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Cervical cancer causes an estimated 265,000 deaths annually, 90% of which 
occur in developing countries.  To reduce the global burden of cervical cancer, 
screening programs and HPV vaccination are needed worldwide.  Screening 
techniques that have had significant success in high resource settings have failed in 
low-to middle-income countries due to a variety of factors, including lack of highly 
trained personnel and lack of laboratory infrastructure.   
Two alternative methods have been employed for cervical cancer screening 
in low resource settings: visual inspection with acetic acid and human 
papillomavirus (HPV) DNA testing.  While both methods are promising, they both 
suffer from low specificity.  In this thesis, I explored the ability of the high-resolution 
microendoscope (HRME) to discriminate between neoplastic cervical precancerous 
lesions and benign conditions in vivo in a pilot study of 59 patients in Barretos, 
Brazil.  By calculating mean nuclear eccentricity and area, neoplastic lesions were 
discriminated from benign conditions with 92% and specificity of 77%.  Further, I 
designed a new mobile-phone based HRME which reduced the size of the HRME by a 
factor of four and the prototype cost from $5,000 to $1,700.   
 
 
In addition to imaging techniques, I explored low-cost immunoassays to aid 
both in cervical cancer screening and HPV vaccination efforts.  Detection of the HPV 
oncoprotein E7 in cervical swabs may offer more specificity than HPV DNA testing, 
but current testing is both time and equipment intensive.  I have developed a paper-
based platform for running highly sensitive immunoassays without the need for 
sophisticated laboratory equipment.  In a proof-of-principle malaria antigen assay, 
this device achieved equivalent limit-of-detection to a standard ELISA.  Additionally, 
I present a modified version of this device for a serological HPV antibody test.  In a 
pilot study of 24 volunteers, the test correctly identified those who had received two 
or more HPV vaccines with 100% accuracy.  Such a test is needed to reduce 
unnecessary revaccination and to promote efficient vaccination in settings with 
poor medical records.  
This work provides an improvement upon the HRME imaging technique and 
a highly sensitive point-of-care molecular diagnostic platform to aid in cervical 
cancer screening, detection and prevention in low-resource settings.  The 
preliminary results from clinical pilot studies provide the foundation for further 
work to help reduce the global cervical cancer burden.  
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 Chapter 1
Chapter 1: Introduction 
1.1. Overview 
Cervical cancer is a major global health concern that disproportionally affects 
women in low resource settings.  Of the estimated 265,000 cervical cancer deaths in 
2012, 90% occurred in developing countries1.   The primary reason for the 
discrepancy is lack of access to screening programs.  The Papanicolaou test allows 
for early detection and subsequent treatment of precancerous lesions.  However, 
developing countries typically lack the required laboratory infrastructure and 
human and economic resources necessary to implement screening programs.  As 
virtually all cervical cancer is caused by the human papillomavirus (HPV), the 
development of HPV vaccines offers the opportunity to significantly reduce the 
burden of this disease.  However, the full benefits of the HPV vaccine will not be 
realized for decades.  Alternative screening technologies have been shown to be 
effective in low-resource settings including visual inspection with acetic acid (VIA) 
 2 
and HPV DNA screening.  Unfortunately, both of these techniques have a low 
positive-predictive value, leading to substantial overtreatment when used as part of 
a screen-and-treat program.  To reduce the burden of cervical cancer in developing 
countries, low-cost, point-of-care tests to improve the specificity of screening and 
diagnosis of cervical precancer are needed.   
This work explores two categories of devices to address this need.  The first 
is a high-resolution microendoscope (HRME), a device that allows imaging of 
epithelial cell nuclei in vivo.  In this thesis, the performance of this device is 
evaluated in pilot study in Brazil.  Additionally, a new version of this device utilizing 
a mobile phone is described and characterized.  The second is a device for molecular 
testing for HPV oncoproteins.  While the complete development of such a test is 
beyond the scope of this thesis, a proof-of-principle paper-based immunoassay is 
developed with sensitivity equivalent to gold standard laboratory based tests.  
The final goal of this work is to aid in improving the efficiency of HPV 
vaccination programs.  HPV vaccination rates remain low in many countries.  One 
challenge faced in extending vaccine coverage is identifying patients who have not 
yet received vaccination.  This can be difficult in regions with poor medical records 
as self-reporting on HPV vaccination is highly inaccurate2.  A rapid, low-cost test to 
assess HPV immune response is presented in this work to help identify those that 
have yet to receive three doses of the vaccine.    
 3 
1.2. Objective and Specific Aims 
The objective of my research is to improve upon and develop new tools for 
screening and diagnosing cervical cancer at the point-of-care.  To achieve this 
objective, I carried out the following specific aims:   
(1) Evaluate the high-resolution microendoscope’s ability to discriminate 
cervical precancer from benign conditions in a pilot study in Barretos, 
Brazil. 
Previous studies diagnosing cervical pre-cancer with the high-resolution 
microendoscope have utilized nuclear-to-cytoplasmic ratio to separate 
high grade dysplasia from less severe abnormalities.  In this aim I seek to 
evaluate other nuclear morphological parameters in order to optimize 
diagnostic performance.  
(2) Develop a more economical, portable mobile high-resolution 
microendoscope (mHRME). 
The previously reported high-resolution microendoscope relies upon a 
research-grade camera and laptop computer.  In this aim, I seek to 
develop a more economical and more portable high-resolution 
microendoscope by utilizing recent advances in mobile phone technology. 
(3) Develop a platform for a highly sensitive immunoassay amenable to the 
point-of-care 
A highly sensitive point-of-care immunoassay platform is necessary in 
order to develop a human papillomavirus oncoprotein based screening 
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test appropriate for the point-of-care.  In this aim I develop a highly 
sensitive, equipment-free two-dimensional paper network for the 
detection of specific proteins in a plasma sample.  I demonstrated the 
proof-of-concept of this approach with the malarial antigen histidine rich 
protein 2.  
(4) Develop a rapid diagnostic test to determine if an individual has developed 
an immune response consistent with receiving two or more HPV 
vaccinations.  
My final aim is to develop a paper based immunoassay for the detection 
of serum antibodies to the human papillomavirus.  This test is needed to 
improve the efficiency of vaccination programs. 
1.3. Chapter Overview 
This thesis details the assessment of the HRME as a tool to diagnose cervical 
precancer in vivo, the design of a mobile high-resolution microendoscope and the 
development of two paper based lateral flow assays.   
Chapter 2 provides the background and motivation for this project.  The 
background covers cervical cancer etiology, prevention, screening and the role of 
human papillomavirus in the context of cervical cancer.  Chapter two also provides a 
brief overview of novel methods for rapid immunoassays designed for the point-of-
care. 
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Chapter 3 presents a pilot study designed to evaluate the performance of the 
HRME in discriminating between precancerous and benign conditions in 59 patients 
in Barretos, Brazil.  Chapter 4 discusses data from an additional 228 patients 
enrolled in this study.  Chapter 5 details the design and characterization of a mobile-
phone based mHRME to reduce the cost and size of the HRME system.   
Chapter 6 describes a novel two-dimensional paper network to perform a 
highly sensitive immunoassay on paper.  Chapter 7 introduces a rapid diagnostic 
test for determining an individual’s (PV status.  Finally, chapter 8 summarizes the 
work provided here and examines future directions for the research.  
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 Chapter 2
Chapter 2: Background and Motivation 
2.1. Cervical cancer overview 
 Cervical cancer is a major global health concern that disproportionally affects 
low-income countries.  In 2012, there were an estimated 527,600 new cases and 
265,700 deaths attributed to cervical cancer1.  Over 90% of all deaths occurred in 
developing countries1.  Figure 2-1 depicts the incidence of cervical cancer globally3.  
The highest rates are seen in sub-Saharan Africa, Central and South America and 
South-Eastern Asia1,3.   While cervical cancer is not one of the top five most common 
types of cancer in countries with a high or very high human development index 
(HDI), it is the most commonly diagnosed cancer  in countries with the lowest HDI4.    
The discrepancy in both incidence and mortality between highly developed and less 
developed countries can be attributed to the effectiveness of national screening 
programs5.  Cervical cancer screening focuses on detecting precancerous lesions 
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Figure 2-1: Estimated cervical cancer indicence worldwide in 2012. 
Incidence reported in age-standardised rates per 100,0003 
that can be removed before cervical cancer develops, thereby lowering both the 
associated incidence and mortality.5  The rates of cervical cancer in North America 
and Europe prior to the implementation of national Pap screening programs were 
similar to those seen in developing countries today5.     
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2.2. Etiology of Cervical Cancer 
Human papillomavirus (HPV) causes virtually all cases of cervical cancer6–8.  
Approximately 200 strains of HPV have been identified9.  Research has shown that 
persistent infection with 15 of these strains causes nearly all cases of cervical 
cancer8.  Strains 16 and 18 cause approximately 70% of all cervical cancers and 50% 
of grade 3 cervical intraepithelial neoplasia (CIN3)8.  The eight most common HPV 
infections found in cervical cancer specimens, in descending order, are HPV16, 
HPV18, HPV45, HPV31, HPV33, HPV52, HPV58, HPV35 and they are responsible for 
approximately 90% of all cervical cancers worldwide10.   
The human papillomavirus is contained in a protein shell comprised of two 
molecules: L1 and L2.  In addition to these two proteins, the HPV genome has the 
capability to code for six other early proteins: E1, E2, and E4-E710.  Of these 
proteins, the two most critical for oncogenesis are proteins E6 and E711.   In fact, the 
presence of E6 and E7 alone are sufficient for keratinocyte immortalization12.  These 
proteins both code for low molecular weight proteins of ~100 amino acids (E6) and 
~150 amino acids (E7)11.  Understanding the molecular oncogenic process of HPV 
infection can help shed light on the critical nature of these two proteins.  
Unlike most viruses, HPV cannot simply infect a cell and create a progeny 
virus from the same cell.  Instead, the synthesis of new HPV virions occurs due to the 
host cell undergoing mitosis13.  HPV infects only the cells located in the basal cell 
layer of the squamous epithelium via small microwounds.  After infection, the small 
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HPV genomes are established as extrachromosomal elements.  They do not encode 
any enzymes necessary for viral replication and rely on the host cell replication 
proteins13.  After a persistent HPV infection, i.e. those associated with high-grade 
lesions, HPV DNA becomes integrated into the host chromosome.   The proliferation 
of these infected cells is dependent primarily on the retinoblastoma family of 
proteins, specifically p105(RB), p107 and p130.  Thus,  a primary target of high-risk 
E7 is the retinoblastoma (Rb) protein13–15.  While E7 proteins from all HPV strains 
bind Rb, those from high-risk HPV strains do so with much higher affinity11,13,16.  E7 
targets Rb for degradation, leading to the release of transcription factor E2f that 
produces an increase in S phase genes and therefore increased cellular 
proliferation13. However, this high binding affinity of Rb by E7 triggers a response 
from tumor suppressor gene p53.  The activation of p53 leads to reduce cell-growth 
and apoptosis.  To combat this regulatory pathway, the HPV E6 protein targets p53 
for degradation11,13,17.  E5 works in concert with E6 and E7 to facilitate malignant 
proliferataion13.  If the immune system is unable to clear the infection, cervical 
cancer can develop after several decades13.   The molecular pathways described 
above are illustrated in Figure 2-213. 
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There are a variety of abnormalities that may affect the squamous epithelium 
of the cervix.  These abnormalities can be divided into two subgroups. The first 
group consists of benign conditions that do not pose an increased risk of 
progression into invasive cervical cancer. This group includes basal cell hyperplasia, 
immature and mature squamous metaplasia and reserve cell hyperplasia.18  
Abnormalities that pose a significant risk of developing into an invasive neoplasm 
are generally referred to as dysplasia or carcinoma in situ.  Previously, dysplasia 
was simply classified as mild, moderate or severe.   However, current nomenclature 
refers to all degrees of squamous epithelium dysplasia of the cervix as cervical 
intraepithelial neoplasia (CIN).  CIN is further broken down into CIN 1, 
 
Figure 2-2: Molecular mechanism of HPV infection. Hyperproliferation is 
caused by E7 induced degradation of Rb protein.  This hyperproliferation leads to 
p53-induced apoptosis. However, E6 leads to the degradation of p53 allowing 
aberrant proliferation to continue. These events lead to a cascade of disruption of 
cellular checkpoints resulting in the immortalization of the infected cell line13. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer, 
copyright 2010.  
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corresponding to mild dysplasia, CIN 2, moderate dysplasia, and finally CIN 3 which 
includes high grade dysplasia and carcinoma in situ18. 
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Grading CIN is based primarily on the proportion of the epithelium thickness 
that is occupied by undifferentiated neoplastic cells.  In CIN 1 the upper two thirds 
of the epithelium still undergo cytoplasmic differentiation18.   All cells will show 
prominent nucleoli and will be irregular in shape.  However, only cells in the bottom 
third of the epithelium will feature high nuclear-to-cytoplasmic ratio and exhibit 
nuclear crowding.  Surface cells may appear largely normal in appearance aside 
from abnormal nuclei.   Mitotic features are sometimes seen in CIN 1 but typically 
only in the bottom third of the epithelium.  These mitotic features are usually still 
normal in appearance.18  CIN 1 often presents with koilocytes, a change brought on 
by HPV,  in the top layers of the epithelium19,20. CIN 2 is similar to CIN 1 except 
crowded nuclei and high nuclear to cytoplasmic ratio extend beyond the lower third 
of the epithelium.18 Abnormal mitotic features are seen in the bottom two-thirds of 
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the epithelium.  CIN 3 features undifferentiated basaloid cells with nuclear crowding 
to a greater degree than CIN 1 or CIN 2.   Abnormal mitotic features are common and 
often in the upper-third of the epithelium.  This type of C)N ͵ is referred to as ǲsmall cell undifferentiated typeǳ although other types exist18.  In other types of CIN 3, the 
degree of the epithelium that is undifferentiated does not exceed two-thirds and 
other metrics must be used.  Relevant features include lack of stratification and the 
site and abnormality of mitotic features.  These types of CIN 3 that do not have 
undifferentiated cells throughout the entire epithelium still show a lack of 
stratification and abnormal mitotic features at all levels of the epithelium18. The 
underlying cellular changes that occur in the progression from normal squamous 
epithelium to CIN3 are depicted in Figure 2-321. 
 
Figure 2-3: Progression from normal squamous epithelium to cervical 
cancer21. Reprinted by permission from Macmillan Publishers Ltd: Nature 
Reviews Cancer21,  copyright 2007. 
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2.3. Cervical Cancer Prevention  
The incidence and mortality of cervical cancer can be reduced through 
screening methods and HPV vaccination.  Screening methods focus on the detection 
and treatment of cervical intraepithelial neoplasia to prevent the development of 
cancer.  HPV vaccination works by preventing infection of HPV types that cause the 
most cases of cervical cancer.  Both techniques face unique challenges in developing 
countries.  
2.3.1. The Effect of Screening 
In the United States, cervical cancer caused the most cancer deaths in women 
prior to the implementation of cytology based screening programs22.  Since 1930 
and the implementation of Pap testing, mortality due to cervical cancer has dropped 
by 80%23.  This is due primarily to the detection and treatment of cervical pre-
cancer23.   Additionally, screening led to early detection of cervical cancer where 
five-year survival rates are significantly higher22,23.  
The best data for comparing incidence and mortality before and after 
screening program implementation is available for Nordic countries5.  While 
controlled prospective studies do not exist to evaluate the efficacy of Pap smear 
testing, the trends in mortality provide strong evidence that Pap testing has helped 
to substantially reduce the mortality of cervical cancer5,24.  Läärä et al., evaluated the 
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trends in mortality of cervical cancer in Denmark, Finland, Iceland, Norway and 
Sweden during the time period over which cervical screening programs were 
introduced24.  In each country, the mortality rate of cervical cancer fell between 
1965 and 1982.   In Iceland, where coverage was greatest and screening intervals 
were shortest, mortality rates dropped by over 80%.  In Finland the mortality rates 
dropped by 50% and in Sweden by 34%.  In Norway, with only 5% of the country 
covered by organized screening, the mortality dropped by only 5%24. In addition to 
lowering mortality, screening has also substantially reduced the incidence of 
cervical cancer5.  Hakama et al., reported a significant decrease in incidence of 
cervical cancer in Iceland, Finland and Sweden after the implementation of national 
screening programs25.  Lynge et al., reported a 30% reduction in incidence after five 
years of national screening in Iceland26.  While less data is available for comparing 
incidence before and after screening in the United States, cervical cancer incidence 
and mortality have dropped sharply since the introduction of screening in the 
1970s27.  
2.3.2. Screening and intervention in high income countries 
The 2012 guidelines from the American Cancer Society (ACS), American 
Society for Colposcopy and Cervical Pathology (ASCCP) and the American Society for 
clinical Pathology (ASCP) recommend no screening for women under the age of 21. 
From ages 21 to 29 women are encouraged to get a Pap smear every 3 years.  HPV 
testing is not recommended in this age group.  The incidence of HPV is too high in 
females under the age of 30 in the United States for HPV DNA testing to be an 
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effective screening modality22,28.  Many of these cases are only transient infections 
and do not lead to cervical cancer.  These screening guidelines are very effective.  
Modeling predicts a lifetime risk of cervical cancer in the United States to be 
between 31 and 33 cases per 1000 women22.   However, screening every 3 years 
reduces the incidence to 5 to 8 cases per 1000 women. Moreover, early stage 
cervical cancer has an exceptionally high 5-year survival rate of 92%.  Because 
screening catches many cases early, the lifetime risk of dying due to cervical cancer 
when screening is performed every 3 years is only .05 per 1000 women22.  
For women between the ages of 30 and 65, the ACS, ASCCP and ASCP all 
agree that HPV-based and cytology-based testing should be performed every 5 
years.  If it is not feasible to follow this recommendation, they recommend cytology 
screening every 3 years22.   Although Pap testing has been used successfully for 
decades, HPV DNA testing offers a unique ability to improve screening.  
Four large, randomized trials have compared cytology-based cervical 
screening with HPV DNA based screening in Sweden, the Netherlands, England and 
Italy29.  A total of 176, 464 women were randomly assigned to either HPV-based or 
cytology-based screening arms.  The women were followed for a median of 6.5 
years.  The results showed that HPV-based screening was superior to cytology based 
screening.  Specifically, HPV-based screening offered 60-70% greater protection 
against cervical cancer when compared to Pap testing29.  The study also compared 
direct referral to colposcopy based on HPV DNA screening versus HPV DNA 
screening followed by cytological triage.  In cytological triage, patients positive for 
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high-risk HPV DNA testing but negative for cytological testing are referred for 
repeat DNA testing after a rest period.  If the HPV DNA test is still positive, indicating 
a persistent infection, they are then referred to colposcopy. The results showed 
similar efficacy between both methods29.  However, cytological triage offered a 
significant reduction in cost by reducing the number of colposcopies and biopsies.   
  Colposcopically-directed biopsies are the next step in the diagnostic 
process.  During this procedure, dilute acetic acid (3-5%) is applied to the cervix30.   
Abnormal areas of the cervix turn white in the presence of acetic acid, a process 
known as acetowhitening.  While the complete mechanisms of acetowhitening are 
unknown, nuclear protein precipitation plays a major role31.  Acetic acid causes the 
temporary precipitation of nuclear proteins with which it comes in contact.  Due to 
the increased nuclear protein in regions of precancer and metaplasia, this 
precipitation causes a noticeable difference in white light scattering in these 
regions31.  Clinicians identify acetowhite areas using a colposcope, a low-power 
white light microscope30.   Suspicious regions are then biopsied and sent to a 
pathologist for diagnosis30,32.   Biopsies with histopathological diagnosis of CIN2 or 
CIN3 are generally then referred for treatment by a loop-electrosurgicial excision 
procedure (LEEP) to remove the precancerous lesions30 or a cold-knife cone if a 
larger section of tissue must be removed8.    
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2.3.3.  Screening in low-to-middle income countries 
This significant reduction in cervical cancer incidence and mortality has yet 
to be realized in developing countries due to the lack of nationwide screening 
programs33.  There are many barriers to screening programs in low-resource 
settings.  These include competing health needs, lack of financial and human 
resources, poor healthcare and laboratory infrastructure and widespread 
poverty33,34.  Screening and diagnosis in high-income countries relies heavily on 
cytotechnologists and pathologists.  While there are approximately 20,000 people 
for every one pathologist in the United States, there are between 200,000 and 
5,000,000 people per pathologist in countries throughout sub-Saharan Africa, as 
shown in Figure 2-435.  This makes implementation of identical screening and 
 
Figure 2-4: Number of people per pathologist in sub-Saharan Africa35. 
Reprinted with minimal adaptations from The Lancet, vol. 14, Adekunkle et al., ǲ)mprovement of pathology in sub-Saharan Africaǳ , eͳͷ͵, Copyright ʹͲͳ͵, with 
permission from Elsevier.  
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diagnostic programs in low-resource settings very difficult.  
In high-income settings, between 40% and 50% of women have undergone 
routine screening for cervical dysplasia in the last five years, compared to only 5% 
in developing countries34. Establishing high quality cytologic services is particularly 
challenging.  Lazcano-Ponce et al., reported that false negative rates of cytology 
readings across 16 cytologic screening sites in Mexico were as high as 54%36.  In 
addition to the challenges in establishing screening programs, patient follow-up 
after detected abnormalities is poor37. Gage et al., found that only 25% of 183 
women with abnormal cytology findings in San Martı́n, Perú, received appropriate 
follow-up care37. 
  Alternative screening techniques have been developed for low-resource 
settings to eliminate the need for extensive laboratory infrastructure and highly 
trained medical personnel.  These techniques focus on immediate diagnosis, 
eliminating the necessity of patient follow-up for treatment38.  Due to the fact that 
detection and treatment are performed in the same visit, these techniques are referred to as see ǲscreen-and-treatǳ programs.  The most widely studied and 
recommended technique for use in low resource settings is visual-inspection with 
acetic acid38–43.  The test consists of applying dilute acetic acid directly to the cervix 
and examining the cervix for areas of acetowhitening, which constitutes a positive 
VIA test39.  Alternatively, both acetic acid and Lugol’s iodine can be applied in a 
technique called visual-inspection with Lugol’s )odine (VILI)44,45.  Lugol’s iodine, 
which stains glycogen-rich epithelium, provides additional contrast to aid in 
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identifying lesions44.   Normal, mature squamous epithelium contains an abundance 
of glycogen, while CIN, metaplasia and columnar epithelium does not44.   An example 
of lesions identified by VIA and VILI is provided in Figure 2-5.  Identified lesions are 
typically removed immediately with cryotherapy39,46,47, which effectively eliminates 
the progression of the disease in 88% of cases47. More recently, human papilloma 
virus (HPV) DNA testing has been explored for cervical cancer screening in low-
resource settings48.  
 
The World Health Organization recommends alternative screening strategies, 
HPV DNA testing, VIA or VILI, where traditional programs based on Pap testing and 
 
Figure 2-5: Visual inspection with acetic acid and Lugol’s )odine.  (A) 
Colposcopic image of the cervix after the application of 3% acetic acid. Acetowhite 
lesions are indicated with white arrows.  (B) Colposcopic image of the cervix after application of ͷ% Lugol’s )odine.  The same lesions seen in (A) are visible in (B) as light areas that do not stain with Lugol’s )odine. These lesions are indicated with 
white arrows. Images courtesy of Dr. Jose Humberto, Barretos Cancer Hospital and 
Dr. Kathleen Schmeler, University of Texas MD Anderson Cancer Center 
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diagnosis have failed to be implemented43.  However, HPV testing, VIA and VILI all 
have limited specificity leading to significant overtreatment.  In a study of 31,343 
women screened with VIA in rural India, VIA significantly reduced both the 
incidence and mortality of cervical cancer compared to the control group who 
received only education regarding cervical cancer signs, symptoms and screening49.   
However, VIA had a positive predictive value (PPV) of only 9.2% for high-grade 
cervical precancer or cancer49. In 2009 Sankaranarayanan et al, reported a cluster-
randomized study of 131,746 women in rural India assigned to received HPV 
testing, cytologic testing, VIA or standard of care (cervical cancer education)50.  
While both HPV testing and VIA significantly decreased incidence and mortality of 
cervical cancer, the PPV were 11.3% and 7.4%, respectively50.  These low positive 
predictive values translate to significant overtreatment in a screen-and-treat 
program.  
VIA and VILI bother suffer from low specificity because they are subject to 
false positives from benign conditions which do not necessitate treatment; these 
conditions include inflammation and low grade dysplasia (CIN1).  HPV DNA testing 
lacks specificity because it cannot differentiate between a transient and persistent 
HPV infection.51  The detection of the oncoprotein E7 in liquid-based cytology may 
help discriminate persistent HPV infections from transient infections52.  However, 
the current method for detecting E7 requires a time- and equipment-intensive 
enzyme-linked immunosorbent assay (ELISA)52.  Before an E7 test can be designed 
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for use in resource constrained settings, a rapid instrument free ELISA platform is 
needed.  
2.3.4. High-Resolution Microendoscopy for the Detection of Cervical 
Precancer 
In an attempt to improve the specificity and positive predictive value of 
biopsy-free cervical precancer diagnosis, flexible fiber optic microscopes have been 
developed to provide real time images of the morphologic features of neoplasia in 
vivo.  High-resolution optical techniques can image tissue with sub-cellular 
resolution to evaluate changes in epithelial morphology53–56. The Richards-Kortum 
group has developed a high-resolution microendoscope (HRME) capable of imaging 
epithelial cells in vivo57–59.  
The HRME, shown in Figure 2-6, is a fiber-optic fluorescence microscope. An 
LED provides excitation light that is collimated and directed into the fiber bundle. 
 
Figure 2-6: The high-resolution microendoscope59. (A) Schematic of the 
HRME. (B) Photograph of the HRME.  
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The fiber bundle is placed is placed directly in contact with the epithelial tissue of 
interest.  Emitted light is collected through the same fiber bundle, filtered and 
focused onto a charge-coupled device (CCD).  Utilizing the exogenous contrast agent 
proflavine, nuclear features including area, shape and spacing can be observed in 
real time without the need for biopsy.  Proflavine is a fluorescent topical antiseptic 
with a peak excitation wavelength of 445 nm and peak emission wavelength of 515 
nm that selectively stains cell nuclei.60.   
Pilot studies of this technology have demonstrated the potential to 
discriminate between neoplastic and non-neoplastic tissue in a variety of organ 
sites, including the esophagus61–63, the oral cavity64,65, and uterine cervix60,66.  Using 
image analysis software, the nuclear-to-cytoplasmic ratio and other morphological 
parameters can be computed for each HRME image.  This ratio increases as cells 
undergo precancerous changes, providing an objective metric to discriminate 
between benign and precancerous images.  This strategy has been used to evaluate 
the HRME as a method to increase the specificity of VIA in two pilot studies in China 
and Botswana60,66. 
Pierce et al. utilized the HRME to examine 173 patients in Shanxi, China.  
Each patient underwent VIA examination followed by colposcopic examination.  All 
acetowhite lesions were imaged with the HRME and biopsied.  Additionally, one 
colposcopically normal site was imaged per patient.  In total, 195 sites were imaged, 
of which 79 were colposcopically abnormal60.  The median nuclear-to-cytoplasmic 
ratio for sites with a high grade dysplasia histopathologic diagnosis (CIN2, CIN3, 
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squamous cell carcinoma) was consistently higher than sites with  non-neoplastic or 
low-grade dysplasia diagnosis (normal, inflammation, metaplasia, CIN1)60.  The 
median nuclear-to-cytoplasmic ratio for the high grade group was .251 versus .164 
for the combined CIN1 and benign group.  Using a nuclear-to-cytoplasmic ratio 
threshold of .185, colposcopically abnormal sites with high grade histopathologic 
diagnosis were separated from all other colposcopically abnormal sites with 100% 
sensitivity and 65% specificity60.  Additionally, only 8.4% of colposcopically normal 
sites exceeded this threshold.  However, these sites had no corresponding biopsies 
so no definitive diagnosis is known.  Quinn et al., reported a similar study at the 
Princess Marina Hospital in Botswana66.  In this study, HRME images from 44 sites 
were obtained.  These sites consisted of both colposcopically normal and 
colposcopically abnormal locations.  Again, the nuclear-to-cytoplasmic ratio was 
computed and compared to histopathologic diagnosis.  A nuclear-to-cyoptlasmic 
ratio threshold of .163 to discriminate between high-grade and not high-grade sites, 
resulted in a  sensitivity of 86% and a specificity of 87%.66  It is important to note 
that the specificity and sensitivity reported for the China study were for only 
colposcopically abnormal sites while the Botswana study included colposcopically 
abnormal and normal sites.  
Despite these encouraging primary results, more research is needed to 
validate and improve the system.  Pierce et al., noted that inflammation also leads to 
an increase in nuclear-to-cytoplasmic ratio60.   In populations with higher rates of 
inflammation, alternative morphological parameters may be necessary to maintain 
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acceptable specificity.  Furthermore, the current HRME system requires a research 
grade camera, a laptop with firewire support, and is not easily transported from one 
location to another59.   Shin et al., reported the ability to use a consumer-grade 
digital single-lens reflex (DSLR) camera in lieu of a computer and research grade 
camera67. However, this eliminates the computer and thus the ability to perform 
image processing to compute objective measurements such as nuclear-to-
cytoplasmic ratio.  Additional methods to reduce the cost and size of the HRME 
while maintain the ability to perform image analysis are needed.  
2.3.5. Human Papillomavirus Vaccination  
There are currently three prophylactic vaccines available for use in the 
protection against HPV strands 16 and 18.  These strands cause an estimated 70% of 
cervical cancers in women1.  One, Cervarix is a bivalent vaccine that offers 
protection from only HPV types 16 and 1868.  The second, Gardasil, is a quadravalent 
vaccine that provides protection from oncogenic types 16 and 18 and non-oncogenic 
HPV types 16 and 11, which are responsible for 90% of cases of genital warts69.  
Both vaccines have been shown to significantly reduce the risk of high-grade CIN 
related to HPV 16 or HPV 18 in large randomized trials70,71.   The Center for Disease 
Control recommends HPV vaccination with one of these two vaccines for all females 
and males at age 11 or 12.  Additionally, vaccination is recommended for all females 
ages 13 to 26 and males ages 13 to 21 who have not yet received the vaccines72. 
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 More recently, a nonavalent vaccine has been introduced.  This vaccine 
includes protection against HPV types 31, 33, 45,52 and 58 in addition to the four 
subtypes of the quadravalent vaccine73.  The addition of these five HPV types 
increases protection from cervical cancer from an estimated 70% to an estimated 
90%73.  All three vaccines require three doses of the vaccine given over a six-month 
period70,71,73.  While HPV vaccines offer tremendous promise to reduce the global 
burden of cervical cancer, effective screening programs remain important for the 
foreseeable future1.  Currently available HPV vaccines are for the prevention of 
infection with HPV and have not shown any benefit to those already infected74.  
The largest obstacle to vaccine coverage in developing countries is the price 
of the vaccine75.  The three-dose series costs approximately $360 in the United 
States75.   Many developing countries are seeking to implement national vaccination 
programs subsidized by the government or with commercial partners76.  In order to 
optimize cost-effectiveness, it is critical that vaccines are provided only to those 
who have yet already received the vaccine.   A study evaluating the accuracy of self-
reporting of HPV vaccination history among adolescents revealed major 
inaccuracies2.  Of the 66 adolescents who had received at least one HPV vaccine, 
only 36 (54%) reported having received the vaccine.  Of the 48 who had received all 
three vaccines, only 17(35%) correctly reported having all three doses2.  Due to the 
under-reporting of HPV vaccine status and the lack of reliable medical records in 
many developing countries, there is a significant possibility of unnecessary 
revaccination.  Currently, an enzyme-linked immunosorbent assay (ELISA) or a 
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neutralization assay are necessary to test if someone has mounted an immune 
response following the administration of the HPV vaccine77.  However, these tests 
require sophisticated laboratory instrumentation and highly trained personnel.  
Low-cost alternatives to these tests are needed to help facilitate efficient vaccination 
programs.  
2.4. Paper based diagnostics    
Paper-based rapid diagnostics tests (RDTs) offer a unique ability to bring 
immunoassay testing to the point-of-care78.  This category of device arose 
specifically in order to develop tests for developing countries meeting the ASSURED 
criteria: affordable, sensitive, specific, user-friendly, rapid and robust, equipment-
free and deliverable to end-users78,79.   Paper-based devices offer several desirable 
properties for meeting these criteria.  Paper is ubiquitous, inexpensive and it 
naturally wicks fluids, providing pump-free flow78.  Lateral flow assays utilize 
nitrocellulose paper to create equipment-free immunoassays80. 
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Lateral flow assays were first established in order to provide an at-home 
pregnancy test80.   These assays, regardless of the application, generally resemble a 
configuration similar to that shown in Figure 2-780.  A direct immunoassay consists 
of a capture antibody immobilized at a test location on the nitrocellulose.  
Downstream, a capture antibody targeted against the species of the detection 
antibody is immobilized on the control line.  Upstream of both test lines is a 
conjugate pad that contains immobilized detection antibody.  The detection 
 
Figure 2-7: Typical layout of a lateral flow assay. A capture antibody is 
adsorbed to the nitrocellulose at the test line.  A dried detection antibody, 
conjuated to a colorimetric particle such as a gold or latex, is located on the 
conjugate pad.  When the sample is placed on the sample pad, it rehydrates 
the detection antibody. If the analyte of interest is found in the sample, it 
binds to the detection antibody and continues to flow down the nitrocellulose 
strip, towards the wicking pad.  It is then capture by the immobilzed antibody 
at the test line.  Unbound detection antibody continues to flow and is 
captured at the control line to indicate a successful test80. Figure reproduced 
from Wong RC, Tse HY, editors. Lateral Flow Immunoassay80. New York: 
Humana Press; 2009. Reproduced with permission of Springer in the format 
Thesis/Dissertation via Copyright Clearance Center. 
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antibody is conjugated to a particle that provides a colorimetric readout, e.g. 
colloidal gold or colored latex80.  In contact with the conjugate pad is a sample pad.  
When the sample, e.g. plasma, is placed on the sample pad it begins to wick onto the 
conjugate pad.  There, it rehydrates the detection antibody.  The detection antibody 
binds to any antigen present and the bound and unbound detection antibody 
continue to wick down the nitrocellulose strip.  Any antigen is captured at the test 
line, and unbound detection antibody continues to flow until the control line.  The 
captured labeled antigen and detection antibody provide visual colorimetric 
readout to the end user80.  
While lateral flow assays offer an excellent solution to performing 
immunoassays at the point-of-care, they often are less sensitive than their 
traditional laboratory ELISA counterparts81. One reason for this is that lateral flow 
assays cannot incorporate an enzyme-linked component due to the direct contact 
between the sample and conjugate particle.  In order to overcome this obstacle, the 
Yager group has produced two-dimensional paper networks (2DPNs)81–84.  Instead 
of only containing a single linear nitrocellulose channel, 2DPNs incorporate 
nitrocellulose legs perpendicular to the primary nitrocellulose test strip.  These legs 
allow for the sequential delivery of reagents, as illustrated in Figure 2-8.  Sequential 
delivery of reagents at the test zone enables more sophisticated assays, including 
gold enhancement and enzymatic amplification82,85.     Using these methods, Fu et al., 
have developed a 2DPN for the detection of the malarial antigen histidine-rich 
protein 2.  They report a limit of detection of 2.9 ng/mL, a four-fold improvement 
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over non-amplified techniques82.  While a significant improvement, the test still falls 
short of the best reported limit of detection of 0.1ng/mL for a standard ELISA for 
this target86. These results are promising, but sensitivity equivalent to standard 
ELISAs will be needed for an effective HPV E7 screening test.  
2.5. Summary 
New techniques are needed for the screening and diagnosis of cervical cancer 
in developing countries. The HRME offers a novel technique for in vivo imaging and 
analysis of nuclear morphology. Initial results suggest that the HRME may offer the 
ability to improve specificity in screen-and-treat programs; however, additional 
data is needed to identify optimal parameters to discriminate between inflammation 
and CIN2 or CIN3.  Furthermore, the HRME design needs to be optimized to reduce 
size and cost.  Complementary molecular diagnostic testing is needed as an initial 
highly sensitive screening test. Point-of-care immunoassays offer the possibility of 
performing HPV oncoprotein based screening and to monitor immune response to 
HPV vaccines.  However, in order for such tests to be developed, a platform to 
improve the sensitivity of currently available lateral flow tests is needed.   
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Figure 2-8: Reagent delivery in two-dimesional paper networks82. Each color 
of food coloring represents a different reagent. The dotted orange square is the 
location of the theoretical test location.  Reprinted with permission from Fu E, 
Liang T, Spicar-Mihalic P, Houghtaling J, Ramachandran S, Yager P. Two-
dimensional paper network format that enables simple multistep assays for use in 
low-resource settings in the context of malaria antigen detection. Anal Chem 
2012;84(10):4574–9. Copyright 2012 American Chemical Society.  
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 Chapter 3
Chapter 3: High-resolution 
microendoscopy: A point-of-care 
diagnostic for cervical dysplasia in 
low-resource settings+ 
3.1. Introduction  
There are more than 520,000 new cases of cervical cancer and 265,000 
related deaths annually 1. More than 85% of cases of and deaths due to cervical 
cancer occur in low- and middle-income countries (LMICs), where cervical cancer is 
the third leading cause of cancer death among women1. Cervical cancer incidence 
and mortality rates are much lower in high-resource settings due to the 
                                                        
 
+ This paper has been published in Grant B, Guerreiro-Fregnani J, Possati-Resende J, 
Scapulatempo-Neto C, Matsushita G, Mauad E, Quang T, Stoler M, Castle P, Schmeler K and Richards-
Kortum R. High-resolution microendoscopy: A point-of-care diagnostic for cervical dysplasia in low-
resource settings. Eur J Cancer Prev 2015. 100 
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implementation of organized screening programs based on Pap and/or HPV testing, 
diagnosis by colposcopy and biopsy, and timely treatment of cervical precancer and 
early-stage cancer.  However, many LMICs have been unable to implement such 
screening programs due to the high cost of necessary infrastructure and lack of 
qualified personnel87,88.  Screening programs are also hampered by loss to follow-up 
of screen-positive women who do not receive accurate diagnosis and timely 
treatment.  As a result, many women still die needlessly due to cervical cancer. 
The World Health Organization recently recommended alternative screening 
strategies of HPV DNA testing or visual inspection with acetic acid (VIA) and screen-
and-treat (S&T) protocols where traditional programs based on Pap testing and 
diagnosis have not been implemented 43.  However, like Pap testing, both VIA and 
HPV testing have limited specificity, i.e., the vast majority of screen-positive women 
do not have cervical precancer or cancer.  HPV detection cannot distinguish between 
benign high-risk HPV infections destined to resolve and those associated with the 
development of preinvasive and invasive cancer.  In a study of 31,343 women 
screened with VIA in India, VIA had a positive predictive value (PPV) of only 9.2% 
for high-grade cervical precancer or cancer49.  In a subsequent study, 
Sankaranarayanan et al. (2009) randomized 131,746 women in rural India to 
receive either a single lifetime screening test using cytology, VIA, HPV testing or 
standard care (cervical cancer health education).  Both VIA and HPV testing were 
associated with low PPV: 7.4% for VIA and 11.3% for HPV testing89. Therefore, using 
only HPV or VIA screening would lead to substantial overtreatment.  
 34 
 
Thus, there is an important need for affordable tools to enable accurate, real-
time diagnosis of cervical precancer and early invasive cancer in screen-positive 
women in low-resource settings.  In an attempt to better detect early cervical 
neoplasia at the point-of-care in screen-positive women, flexible fiber optic 
microscopes have been developed to provide real-time images of the morphologic 
features of neoplasia in vivo.  High-resolution optical techniques can image tissue 
with sub-cellular resolution to evaluate changes in epithelial morphology 53. We 
developed a high-resolution microendoscope (HRME) capable of imaging epithelial 
cells in vivo 57,58. The HRME utilizes a small (1 mm) fiber optic probe placed in direct 
contact with the cervical epithelium, allowing real-time imaging of the underlying 
tissue.  Utilizing the exogenous contrast agent proflavine, nuclear features including 
area, shape and spacing can be observed in real-time without the need for biopsy. 
Pilot studies of this technology have demonstrated the potential to 
discriminate between neoplastic and non-neoplastic tissue in a variety of organ 
sites, including the esophagus 61,62,90, the oral cavity 64,65,91, the colon92 and the cervix 
60,66.  In this study, we evaluate the diagnostic accuracy of the HRME imaging system 
to identify precancerous lesions of the cervix in vivo in a pilot study in Barretos, 
Brazil.  
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3.2. Methods 
3.2.1. Study Overview 
The National Committee for Ethics in Research (CONEP) of Brazil and the 
Institutional Review Boards from Hospital de Câncer de Barretos (Barretos, Brazil), 
MD Anderson Cancer Center, and Rice University (Houston, USA) reviewed and 
approved this study.  Female patients residing in the state of São Paulo, Brazil were 
eligible to participate if they had been referred to Hospital de Câncer de Barretos for 
colposcopy due to a subset of abnormal Pap tests.  Eligible referral Pap tests 
included low-grade squamous intraepithelial lesion (LSIL), high-grade squamous 
intraepithelial lesion (HSIL), atypical squamous cells – cannot exclude HSIL (ASC-H) 
and atypical glandular cells (AGC).  A Pap diagnosis of atypical squamous cells of 
undetermined significance (ASC-US) was generally insufficient for inclusion unless 
the patient had a previous, more severe Pap diagnosis.  Exclusion criteria included 
women who were pregnant, have had a hysterectomy, or were nursing.   
3.2.2. High-resolution Microendoscope 
The high-resolution microendoscope (HRME) is a battery-powered, fiber-
optic fluorescence microscope.  The design of the system has been described in 
detail previously 57,58.  The device is approved only for investigational use.  An image 
of the system is provided in Figure 3-1.  The system is designed to image cervical 
epithelium following topical application of proflavine, a fluorescent contrast agent 
that stains cell nuclei.  Proflavine has a history of safe clinical use as a topical 
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Figure 3-1: Picture of the high-resolution microendsocope 
(HRME) system66 
antiseptic 93, although its use as a contrast agent is investigational.  Proflavine has a 
peak excitation wavelength of 445 nm and a peak emission wavelength of 510 nm.  
The HRME system provides excitation light to the tissue via a blue LED with a center 
wavelength of 455 nm.  The light is collimated, filtered and directed into a 1.0 mm 
diameter flexible fiber optic bundle containing 30,000 individual fibers.  Proflavine 
dye is applied topically to stain epithelial cell nuclei and the fiber bundle is placed in 
gentle contact with the tissue site to be imaged.  Proflavine fluorescence is then 
captured by the 
same fiber optic 
bundle, filtered, 
and focused onto a 
battery-powered 
charge-coupled 
device (CCD) 
sensor.  The image 
is displayed in real-
time on a laptop 
computer which 
also controls image 
acquisition.  The 
CCD captures video 
at 10 frames per 
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second. 
 
3.2.3. Study Procedure 
After consenting to participate in the study, each woman was first 
interviewed by a trained healthcare professional to obtain basic demographic 
information.  All women received a urine based pregnancy test before proceeding 
with the study.  Next, routine colposcopy with 5% acetic acid was performed to 
identify acetowhite lesions on the cervix.  If acetowhite lesions were identified, 
0.01% proflavine in sterile water was applied to the cervix using a spray bottle.  The 
cervix was wiped with a cotton swab to ensure even distribution of proflavine.  The clinician then applied ͷ% Lugol’s )odine to the cervix, and any lesions that excluded 
iodine staining were noted.  Finally, 0.01% proflavine was re-applied to ensure a 
strong fluorescence signal.  The clinician then placed the distal tip of the fiber probe 
in gentle contact with each suspicious region identified during colposcopy and 
acquired a two second video from each site.  The clinician also placed the HRME 
probe and acquired videos from a site which appeared by colposcopy to be normal 
squamous epithelium.  The entire imaging procedure lasted less than ten minutes.  
After HRME imaging was performed, a biopsy was obtained from each suspicious 
site and submitted for histopathological diagnosis.   
Each biopsy was examined by two pathologists at Hospital de Câncer de 
Barretos, referred to in this manuscript as the clinical pathologists.  All biopsies 
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were also independently reviewed by a study pathologist at the University of 
Virginia.  Samples were classified as normal, inflammation, cervical intraepithelial 
neoplasia (CIN) grade 1 (CIN1), CIN grade 2 (CIN2), CIN grade 3 (CIN3) or cancer 
using standard criteria 94. All pathologists were blinded to the HRME images and to the other pathologists’ diagnoses.  The two clinical pathologists came to a consensus 
diagnosis in any cases where their initial diagnoses disagreed.  In cases where the clinical pathologists’ and study pathologist’s diagnoses did not agree, samples were 
classified as the more severely neoplastic diagnosis. 
3.2.4.  Data Analysis 
A researcher blinded to the histopathologic diagnosis selected the highest 
quality frame from each video with respect to clarity of focus.  Sites were excluded 
from further analysis if more than 50% of the HRME image in the highest quality 
frame was out of focus or obscured by debris at the probe tip.  The remaining 
images were analyzed using a custom Matlab 2012b script, designed to segment 
individual nuclei in each image and to quantify nuclear area and eccentricity.  
Briefly, the program first finds the outline of the fiber bundle and removes signal 
outside its boundary.  Next, the image is Gaussian filtered to remove image artifacts 
due to the outline of individual fiber cores in the image.  After the Gaussian filter is 
applied, a top-hat filter is used to reduce background and increase contrast between 
nuclei and the background. This new image is used to automatically select a region-
of-interest (ROI).  The ROI is calculated automatically by first selecting the entire 
area inside the fiber boundary.  Next, areas of the image that are too dimly lit, 
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saturated, or homogenous are removed from the ROI.  After the final ROI is 
determined, a binary threshold is applied to segment individual nuclei from the background.  The threshold value is chosen automatically by Otsu’s method95.  The 
nuclear-to-cytoplasmic ratio, mean and median nuclear area, standard deviation of 
the nuclear area, median perimeter and median eccentricity are calculated and 
recorded for each image.   
A test of trend 96 was used to examine the relationship between HRME 
categorizing the lesion as positive (CIN2+) and severity of histopathologic diagnosis by the study pathologists. A Fisher’s exact test was used to test for differences in 
HRME positivity for CIN2 or more severe diagnoses (CIN2+) vs. <CIN2 diagnoses.  
Sensitivity, specificity, and odds ratio (OR) with 95% confidence intervals (95%CI) 
were calculated for HRME detection of CIN2+ and CIN3 or more severe diagnoses 
(CIN3+).  P values of <0.05 were considered statistically significant.   
3.3. Results  
 40 
 
A total of 59 patients were enrolled in the study between June 17, 2013 and 
June 21, 2013.  All patients successfully underwent HRME imaging without any 
adverse events.  The median age was 34 (range: 18-67).  Referral Pap tests ASC-US 
(n =1, 1.7%), LSIL (n=7, 11.9%), HSIL (n = 20, 33.9%), ASC-H (n=29, 49.2%) and 
AGC (n=2, 3.4%).  HRME images were obtained from 84 colposcopically abnormal 
sites and 59 colposcopically normal sites.  Fifty-nine of the 84 colposcopically 
 
Figure 3-2 Representative HRME images of cervical epithelium stained with proflavine 
and Lugol’s iodine.  (A) HRME image of colposcopically normal site shows round, small,  
evenly spaced nuclei. (B-F)  HRME images of colposcopically abnormal sites.  (B) HRME image 
of a site with histologic diagnosis of inflammation, characterized by evenly spaced, small, 
crowded nuclei.  (C) HRME image of a site with histologic diagnosis of CIN1, with slightly 
enlarged, evenly spaced nuclei.  (D) HRME image of a site with histologic diagnosis of CIN2 with 
enlarged, crowded, pleomorphic nuclei.  (E) HRME image with a histologic diagnosis of CIN3 
showing similar features to CIN2, with more pronounced nuclear crowding and pleomorphism. 
(F) HRME image of a second site diagnosed as CIN3 with very prominent vessels visible. 
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abnormal sites imaged and biopsied were adequate for evaluation.  Forty-nine of the 
59 colposcopically normal sites imaged passed quality control review.  Table 3-1 
summarizes the colposcopic impression and consensus histologic diagnosis for the 
sites imaged with the HRME that passed quality control review.   
Table 3-2 summarizes the agreement between the clinical and study 
pathologists for the sites with images passing quality control (QC) review.  For 75% 
of these sites, the diagnoses provided by the clinical and study pathologists were 
identical.  In cases where the diagnosis differed, they did not disagree by more than 
one degree, e.g. CIN2 versus CIN3.   
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Figure 3-2 shows representative HRME images for each histologic diagnosis, 
progressing from normal squamous epithelium in Figure 3-2A to CIN3 in Figure 
3-2F.  The figure illustrates the changes seen in underlying nuclear size, shape and 
crowding.  While normal tissue shows small, well-spaced uniform nuclei, high grade 
dysplasia features large, crowded, irregularly shaped nuclei.  In some cases, HRME 
images of CIN3 and cancer show prominent vessels (Figure 3-2F).  In this study, 
vessels were present in three of the 24 cases of CIN3 or cancer and were not present 
in any other histological classification.  
Colposcopic 
Impression 
Histologic Diagnosis 
Number of Sites 
Measured Passing 
QC Review 
Number of sites 
HRME Positive 
% HRME 
positive 
Normal NA 49 3 6% 
Abnormal Normal/ 
Inflammation 
8 2 25% 
Abnormal CIN1 14 3 21% 
Abnormal CIN2 13 11 85% 
Abnormal CIN3 21 20 95% 
Abnormal Cancer 3 3 100% 
Table 3-1 Fraction of sites classified as positive by HRME image analysis versus colposcopic 
impression and histologic diagnosis. The HRME system was used to collect images from 108 sites in 
59 patients referred to Hospital de Câncer de Barretos between June 17, 2013 and June 21 on the basis 
of an abnormal Pap test.  The colposcopic impression, histopathologic diagnosis and HRME diagnosis 
are reported for each site passing quality control. 
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We evaluated the ability of each quantitative nuclear feature to discriminate 
between <CIN2 and CIN2+.  Two parameters – mean nuclear area and median 
nuclear eccentricity – provided the clearest delineation between neoplastic and 
non-neoplastic sites.  Eccentricity is a measure of the circularity of an object; the 
higher the eccentricity the less circular the object is.  As cells progress from low-
  
Study Pathologist 
  
Negative C)Nͳ C)Nʹ C)N͵ Cancer Total 
Clinical
 Patholo
gists 
Negative 8 25% HRME 
+ 
1 
0% HRME+ 
0 0 0 9  
C)Nͳ 6 
17 % HRME+ 
7 
29% HRME+ 
3 
67% HRME+ 
0 0 16  
C)Nʹ 0 0 10 
90% HRME+ 
2 
100% 
HRME+ 
0 12 
C)N͵ 0 0 2 100% 
HRME+ 
17 
94% HRME+ 
0 19 
Cancer 0 0 0 1 100% 
HRME+ 
2 
100% 
HRME+ 
3 
Total 14 8 15 20 2 59 
Table 3-2 Comparison of the histologic diagnosis between the clinical pathologists and study 
pathologist for all 59 colposcopically abnormal sites.  The clinic pathologist designates the two 
pathologists working at Hospital de Câncer de Barretos and the study pathologist refers to a 
blinded third pathologist at the University of Virginia.  The bold text in the boxes along the diagonal 
indicates cases where the clinical and study pathologists agreed exactly on the histologic diagnosis.  
In each category, the fraction of sites which were classified as neoplastic based on features of the 
HRME image is indicated.    
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grade to high-grade disease, their eccentricity and mean nuclear area both increase 
97.  Figure 3-3 shows a scatter plot graph of median nuclear eccentricity vs mean 
nuclear area for the 108 sites passing QC.  Using these two parameters, we were 
able to separate the 59 biopsied sites into <CIN2 and CIN2+ populations with a 
sensitivity of 92% (34/37, 95% CI = 78.1% - 98.2%) and a specificity of 77% 
(17/22, 95% CI = 54.6% to 92.1%).  The OR, as a measure of association and 
accuracy of HRME with CIN2+, was 38.5 (95% CI = 8.2-181).  There was a significant 
trend of increasing HRME positivity with increasing severity of diagnosis (ptrend < 
0.001), and HRME positivity was strongly associated with a CIN2+ diagnosis (p < 
0.001).  Using the same cutoff to separate biopsied sites into < CIN3 and CIN3+ 
results in a sensitivity of 96% (23/24, 95% CI = 78.8% to 99.3%) and a specificity of 
54% (19/35, 95% CI = 36.7% to 71.2%).  The OR for CIN3+ was 27.3 (95% CI = 3.3 – 
225).   
Figure 3-3 also shows the value of these parameters for the 49 
colposcopically normal sites.  All but three colposcopically normal sites were 
classified as non-neoplastic.  Table 3-1 lists the fraction of sites which were 
classified as neoplastic according to these HRME parameters by colposcopic 
impression and histologic diagnosis, where available.  All of the sites diagnosed as 
cancer and 95% of sites diagnosed as CIN3 were correctly classified as neoplastic 
based on the HRME image.  Only 6% of colposcopically normal sites were classified 
as HRME positive.   
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We also explored whether the fraction of sites classified as neoplastic was 
related to inter-observer agreement between the clinical and study pathologists.  
Figure 3-4 shows a bar graph of the fraction of sites classified as neoplastic by the 
HRME versus the histologic diagnosis of the pathologists.  In cases where the clinical 
and study pathologists both provided a diagnosis of CIN1, only 29% of samples were 
classified as neoplastic based on the HRME image.  In contrast, in cases where the 
pathologists provided differing diagnoses of CIN1 or CIN2, 67% of samples were 
classified as neoplastic by HRME imaging.  Similarly, in cases where the clinical and 
study pathologists both provided a diagnosis of CIN2, 90% of samples were 
classified as neoplastic based on the HRME image.  In contrast, in cases where the 
 
Figure 3-3 Scatter plot of mean nuclear area versus median nuclear eccentricity 
calculated from HRME images for each site.  The gold standard histologic diagnosis for 
colposcopically abnormal sites that were biopsied is indicated by the marker shown in the 
legend.  The gold standard histologic diagnosis is defined as the more severe diagnosis between the clinical pathologists’ consensus diagnosis and the study pathologist’s diagnosis.  The black 
line was selected to maximize accuracy for separation of neoplastic (CIN2+) and non-neoplastic 
(<CIN2 i.e., normal, inflammation, CIN1) sites.   
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pathologists provided differing diagnoses of CIN2 or CIN3, 100% of samples were 
classified as neoplastic by HRME imaging.  Thus, if either the clinical or study 
pathologist classified the biopsy as high grade, the HRME diagnosis was more likely 
to be positive.  
 
3.4. Discussion  
This pilot study demonstrates the ability to use parameters derived from 
HRME images to objectively discriminate between non-neoplastic and neoplastic 
cervical tissue with a low false negative and false positive rate.  Two of the three 
 
Figure 3-4 Bar graph depicting the percent of sites classified as neoplastic based 
on features of the HRME image versus clinical and study pathologists’ histologic 
diagnosis. 
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sites that were falsely classified as negative using HRME image parameters had a 
histologic diagnosis of CIN2, a less reproducible and reliable diagnosis than CIN3 98.  
One additional possible cause for the false negatives in this study is imperfect 
correlation between the imaged location and the biopsy location.  In the future, 
mosaicking could be implemented to acquire HRME images from a larger field of 
view in the region-of-interest, reducing the chance of missing focal lesions 99. All 
four of the sites (100%) classified as CIN2 by one pathologist and CIN3 by another 
pathologist were classified neoplastic by the HRME algorithm.  However, when the 
clinical and study pathologists agreed on a CIN2 diagnosis, the HRME-based 
algorithm was falsely negative for one of ten sites (10%); when they disagreed 
between a diagnosis of CIN1 and CIN2, one of three (33%) of samples was falsely 
classified as negative.  These results suggest that the HRME-based algorithm may 
identify nuclear changes present in more advanced CIN2 cases; however, a larger 
study is necessary to validate this finding. 
The sensitivity and specificity reported here are for the 59 sites that were 
colposcopically abnormal, i.e., the subset of sites exhibiting acetowhitening.  In a VIA 
screen-and-treat program, all 59 of these sites would be treated, including the 22 
sites that were histologically non-neoplastic.   Only five of these 22 (23%) sites were 
falsely classified as positive by HRME image analysis.  Thus, in this study, the HRME 
would reduce overtreatment compared to using VIA by 77%.  It is not possible to 
determine whether the three HRME images acquired from colposcopically normal 
sites are truly falsely positive because they were not biopsied.  These results 
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support the concept that HRME image parameters could be used to improve the 
specificity of screen-and-treat programs by quantitatively identifying nuclear 
features associated with neoplasia, without requiring a biopsy and pathology 
services. 
The 92% sensitivity and 77% specificity of the algorithm based on HRME 
image parameters reported here compares favorably to a previous study our group 
performed in China (sensitivity = 100% and specificity = 67%) 60.  In the previous 
study, the authors used nuclear-to-cytoplasmic ratio to discriminate between 
neoplastic and non-neoplastic sites.  The majority of the false-positive sites (17/19, 
89%) in the China study were sites with underlying chronic inflammation.  One 
concern was that in low-resource settings, the higher rates of inflammation would 
lead to lower HRME-based specificity.  Indeed, using only nuclear-to-cytoplasmic 
ratio to classify the images acquired in the current study resulted in a sensitivity of 
76% and a specificity of 45%.  We found that utilizing the mean nuclear area and 
median eccentricity helped to reduce the number of false positives.  We hypothesize 
these parameters are less susceptible to change due to inflammation than the 
nuclear-to-cytoplasmic ratio as inflammation can lead to an increase in nuclear-to-
cytoplasmic ratio due to nuclear crowding.  Conversely, nuclear area remains small 
and nuclei do not exhibit significant pleomorphism.  The addition and utilization of 
these parameters helped to improve both sensitivity and specificity in this study 
population; however, more data are needed to validate including this parameter in 
HRME image classification. 
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While the results of this study are encouraging, there are limitations.  Only 59 
women were included in this pilot study.  A larger prospective study is necessary to 
validate the algorithm.  In addition, lesions that are not visible by VIA will be missed 
by this modality.  Furthermore, the HRME images from 30% of sites that were 
biopsied did not pass quality control.  This would result in an unacceptably high 
number proportion of patients not receiving a diagnosis by HRME.  To eliminate this 
problem, the software in future iterations of the device will provide feedback to the 
user to indicate whether an in-focus image was acquired.  If the image is out of 
focus, the user will be prompted to acquire another image until an image of 
sufficient quality is obtained.  After an image of sufficient quality is obtained, it will 
be analyzed immediately to provide an objective classification of the underlying 
tissue as low-grade or high-grade.  The end user will not be required to interpret the 
mean nuclear area and median eccentricity but will instead receive a direct diagnosis of ǲhigh gradeǳ or ǲnot high gradeǳ from the software.  This automated 
software has been developed and will be validated in a future study.   The HRME 
system costs approximately $5,000 and the cost of reagents is negligible.  We are 
currently testing versions of the device that cost under $2,000 to better facilitate 
their use in low-resource settings.     
Further evaluation of the HRME modality in a large prospective study is 
ongoing. Our results suggest that HRME imaging may provide a low-cost, accurate, 
point-of-care alternative to colposcopy and directed cervical biopsies for the 
diagnosis of cervical dysplasia in lower-resource settings, where there is often a lack 
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of colposcopy and pathology services.  Some settings may not accept a screen-and-
treat strategy due to concerns of overtreatment and yet lack the diagnostic 
capacities to provide a biopsy-proven diagnosis. In these settings, we envision the 
technology being used in conjunction with VIA or HPV DNA screening.  Women who 
screen positive would then be evaluated with the HRME for immediate treatment if 
indicated, thereby reducing losses to follow-up.   
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 Chapter 4
Chapter 4: High-resolution 
microendoscopy: A point-of-care 
diagnostic for cervical dysplasia in 
low-resource settings, continued 
4.1. Overview 
An additional 228 patients were enrolled in the study to evaluate the 
diagnostic performance of the HRME.  The motivation and aims are as described in 
the preceding chapter.  
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4.2. Methods 
4.2.1. Study Overview 
The National Committee for Ethics in Research (CONEP) of Brazil and the 
Institutional Review Boards from Hospital de Câncer de Barretos (Barretos, Brazil), 
MD Anderson Cancer Center, and Rice University (Houston, USA) reviewed and 
approved this study.  The inclusion and exclusion criteria and study procedure are 
identical to those outlined in Chapter 3.  The high-resolution microendoscope 
(HRME) used is the same device described in Chapter 3.  The study procedure is 
identical to that in chapter 3, with one exception; in this study, two pathologists at 
Hospital de Câncer de Barretos independently provided histopathological diagnosis 
for each biopsy.  Biopsies were classified as metaplasia, inflammation, cervical 
intraepithelial neoplasia (CIN) grade 1 (CIN1), CIN grade 2 (CIN2), CIN grade 3 
(CIN3) or cancer using standard criteria 94. In cases where the two pathologists 
disagreed, they reviewed the cases together and came to a consensus diagnosis.  In 
the event that the pathologists were unable to determine if a biopsy was CIN2 vs 
CIN3, the final diagnosis used in this analysis is designated as CIN2/3. 
4.2.2. Image Analysis 
One movie frame was selected from each biopsy location. A researcher 
blinded to histopathological diagnosis selected a frame they deemed to be of the 
highest quality and most dysplastic appearing image from each imaging site. Images 
in which greater than half of the field-of-view was not in focus or in which greater 
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than half of the field-of-view was occluded by large debris were manually identified 
and excluded from further analysis.  The remaining images were analyzed using a 
custom Matlab 2012b script.  First, the user manually selected the outline of the 
fiber bundle.  Signal outside of this boundary was disregarded.  A Gaussian filter was 
applied to remove artifacts from individual fiber cores.  Next, a top-hat filter was 
applied to reduce background variance and increase contrast.  From this image, a 
region-of-interest (ROI) for further analysis was automatically determined.  The ROI 
was calculated by taking the area inside of the fiber and removing any saturated, 
dimly lit, or homogenous areas90.  Inside the ROI, a binary threshold was applied to 
separate nuclei from the background.  The threshold was determined automatically using Otsu’s method 95.  The nuclear-to-cytoplasmic ratio, mean nuclear area, 
median nuclear eccentricity and number of nuclei were calculated for each ROI.  To 
quantify image quality in order to facilitate automatic image quality control, the 
Michelson contrast and average intensity of each ROI was calculated.  Additionally, 
abnormal nuclei were identified in each image.  A nuclei was classified as abnormal 
if its area was greater than 195 µm2 and its eccentricity was greater than 0.65.  
These thresholds were selected based on comparing the mean nuclear area and 
nuclear eccentricity of non-neoplastic and neoplastic sites imaged in Chapter 3.   
Based on this information, the percent of nuclei which were classified as abnormal 
was calculated for each image.  Finally, the number of abnormal nuclei per unit area 
of the ROI was also calculated.  Images with a Michelson contrast of less than 0.15 
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and an average intensity of less than 40 were automatically excluded from further 
analysis. Images with less than 100 nuclei in the field-of-view were also excluded. 
Four methods were compared for classifying images as non-neoplastic 
(inflammation, metaplasia, and CIN1) vs neoplastic (CIN2, CIN2/3, CIN3, cancer).  
The first method used the parameter of mean nuclear area and median eccentricity 
for classification; as described in Chapter 3.  The same cutoff line using data from 
the previous 59 patients was used.  The second method used nuclear-to-cytoplasmic 
ratio to classify images as non-neoplastic or neoplastic.  The third method used the 
percent of nuclei that were abnormal in the ROI and the final method used the 
number of abnormal nuclei per unit area of the ROI as classification parameters.  For 
the second, third and fourth methods the cutoff was chosen as the highest cutoff-
value that achieved 90% sensitivity.  For each method, a test of trend96 was used to 
examine the relationship between a neoplastic HRME diagnosis and the severity of 
the histopathological diagnosis.  Sensitivity, specificity, and odds ratio (OR) with 
95% confidence intervals (95% C.I.) were calculated for HRME detection of CIN2 or 
more severe diagnosis (CIN2+) + and CIN3 or more severe diagnoses (CIN3+).  P 
values of <0.05 were considered statistically significant.    
4.3. Results  
A total of 228 patients were enrolled in the study between September 8, 
2014 and January 26, 2015.  All patients successfully underwent HRME imaging 
without any adverse events.  HRME images were obtained from 253 colposcopically 
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abnormal sites.  Images from twenty three of these sites were removed by the 
automatic quality control algorithm. Twenty two of these images were removed 
because they were below the Michelson contrast and average intensity metrics.  One 
was removed due to an insufficient number of nuclei found in the image. An 
additional eleven images were removed through the manual QC process. The 
distribution of the consensus histopathologic diagnosis for the remaining 219 sites 
is as follows: eleven inflammation (5%), four metaplasia (2%), one-hundred and 
one CIN 1 (46%), forty CIN 2 (18%), seven CIN 2/3 (3%), forty six CIN 3(21%), eight 
squamous cell carcinoma (4%) and two adenocarcinoma (1%).  
The result of the four methods for classifying images as neoplastic or non-
 
Figure 4-1: Classification of sites as neoplastic or non-neoplastic by four different 
methods. (A) Classification by median eccentricity and mean nuclear area. (B) Classification by 
nuclear-to-cytoplasmic ratio (C) Classification by percent of nuclei that are abnormal (D) 
Classification by number of abnormal nuclei per unit area 
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neoplastic is shown in Figure 4-1.  The corresponding sensitivities, specificities, test 
of trend and odds ratio are provided in Table 4-1.  All methods showed a significant 
trend (p<0.05) between increasing severity of histopathologic diagnosis and HRME 
positivity.  Of the three methods achieving a minimum sensitivity of 90%, the 
specificity was greatest using the number of abnormal nuclei per unit area (38.9%), 
followed by NC ratio (37.1%) and percent of total nuclei that were abnormal 
(26.7%).  If the cutoff is adjusted to achieve greater than 90% sensitivity using mean 
area and median eccentricity, the specificity for this method drops to 30.2%.    
 57 
 
The association of HRME positivity with CIN2+ was evaluated using OR.  The 
OR for CIN2+ was 6.6 (95% C.I. = 3.0 – 14.4) using the number of abnormal nuclei 
per unit area, 6.2 (95% C.I. = 2.8 to 13.4) using NC ratio, 3.8 (95% C.I. =1.7 to 8.5) 
using fraction of nuclei that were abnormal and 2.4 (95% C.I. = 1.3 to 4.3) using 
 HRME positive by 
number abnormal 
per unit area 
HRME positive by 
fraction of nuclei 
that are abnormal 
HRME positive by 
mean area and 
median 
eccentricity 
HRME positive by 
NC ratio 
Inflammation 9/11 (81%) 9/11 (81%) 6/11 (54%) 8/11  (72%) 
Metaplasia 1/4 (25%) 3/4 (75%) 3/4 (75%) 1/4 (25%) 
CIN1 61/101(59%) 73/101(71%) 60/101 (56%) 64/101 (62%) 
CIN2 33/40 (83%) 35/40 (87.5%) 30/40 (75%) 33/40 (83%) 
CIN2/3 6/7 (86%) 5/7 (71%) 4/7 (57%) 6/7 (86%) 
CIN3 45/46 (98%) 45/46(98%) 38/46 (83%) 45/46 (98%) 
Squamous Cell 
Carcinoma 
8/8(100%) 7/8 (87.5%) 6/8 (75%) 8/8(100%) 
Adenocarcinoma 2/2 (100%) 2/2 (100%) 2/2 (100%)  2/2 (100%) 
Sensitivity CIN2+ 
(95% C.I.) 
91.3% 
 (84.1% – 95.9%) 91.3%  (84.1% – 95.9%) 77.7% (68.4%– 85.3%) 91.3% (84.1 % to 95.9%) 
Specificity CIN2+ 
(95% C.I.) 
38.9% 
(29.9% - 48.2%) 
26.7% 
(18.9% - 35.7%) 
40.5% 
(31.5% - 50.0%) 
37.1% 
(28.3% to 46.5%) 
Sensitivity CIN3+ 
(95% C.I.) 
98.2%  
(90.5 – 100%) 96.5% (87.9% - 99.6%) 82.1% (69.6%-91.1%) 98.2%  (90.5 – 100%) 
Specificity CIN3+ 
(95% C.I.) 
32.5% 
(25.4% - 40.3%) 
23.3% 
(17.1% - 30.6%) 
36.8% 
(29.4% - 44.7%) 
31.52 % 
(24.5% to 39.2%) 
Odds Ratio CIN2+ 
(95% C.I.) 
6.6 
(3.0 to 14.4) 
3.8 
(1.7 to 8.5) 
2.4 
(1.3 to 4.3) 
6.2 
(2.8 to 13.4) 
Odds Ratio CIN3+ 
(95% C.I) 
26.5 
(3.6 to 196.7) 
8.2 
(1.9 to 35.2) 
2.7 
(1.3 to 5.7) 
25.0 
(3.4 to 186) 
Test of Trend P < 0.001 P< 0.025 P<0.025 P<0.001 
Table 4-1 Comparison of performance of four different methods for classifying HRME 
images 
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median area and eccentricity.  The odds ratio for HRME positivity with CIN3+ was 
26.5 ( 95% C.I. = 3.6 to 196.7) for number abnormal nuclei per unit area, 25.0 (95% 
C.I. = 3.4 to 186.0) for NC ratio, 8.2 (95% C.I. = 1.9 to 35.2) for fraction of nuclei that 
were abnormal, and 2.7 (95% C.I. =1.3 to 5.7) for mean area and median 
eccentricity.    
4.4. Discussion 
The specificity was significantly lower using any method presented here 
compared to the reported specificity of 77% achieved for the first 59 patients100.  
Cut-off values for the three new classification algorithms were chosen to ensure a 
minimum of 90% sensitivity.  This decision was made because it is critical that the 
HRME does not incorrectly classify high grade dysplasia as non-neoplastic.  This 
choice, however, resulted in low specificity for all classification methods.  One major 
difference between the population of the pilot study of the first 59 patients and the 
population reported in this study is the fraction of sites with a non-neoplastic 
histopathological diagnosis.  In the first study, only 22 of 59 sites (37%) were 
classified as non-neoplastic.  In this study, 116 of 219 sites analyzed were non-
neoplastic (53%).  There was a large degree of heterogeneity amongst these non-
neoplastic sites.  This is evident by the large variation seen across all parameters for 
non-neoplastic sites, as shown in Figure 4-1.   
The challenges this heterogeneity presents are evident in the example 
images in Figure 4-2.  Figure 4-2A shows an HRME image of a site with a 
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histopathologic diagnosis of CIN1.  Every classification method correctly identified 
this site as non-neoplastic.  Figure 4-2B is an HRME image from a site with a 
histopathological diagnosis of inflammation.  The pathology report also noted the 
biopsy contained only endocervical tissue without any squamous cells.  The densely 
packed columnar cells of endocervical tissue are difficult to distinguish from high 
grade dysplasia using HRME imaging. All four methods incorrectly identified this 
location as neoplastic.  Figure 4-2C shows an HRME image from a site with a 
histopathological diagnosis of CIN1 with metaplasia.  The high nuclear density seen 
in inflammatory conditions in conjunction with the densely packed columnar tissue 
found in metaplastic tissue also presents challenges for HRME imaging. All 
classification algorithms also incorrectly identified this site as neoplastic.  Finally, 
Figure 4-2D shows an HRME image from a site with a histopathologic diagnosis of 
CIN3.  This region was classified as neoplastic using the number of abnormal nuclei 
per unit area method and NC ratio method.  It was incorrectly identified non-
neoplastic by the other two algorithms. Because it is critical to not misclassify high-
grade cases, it is difficult to achieve high specificity with the wide array of cases seen 
in non-neoplastic cervical tissue.  
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Figure 4-2: Challenges in separating HRME images from non-neoplastic sites (A-C) 
from HRME images from neoplastic sites(D).  (A) HRME image from a site diagnosed as 
CIN1. This site was correctly identified as non-neoplastic by all HRME classification 
algorithms. (B) HRME image from a site with a histopathologic diagnosis of inflammation.  
The biopsy showed endocervical tissue without any squamous tissue. All HRME algorithms 
incorrectly diagnosed this as site as neoplastic. (C) HRME image from a site with a 
histopathologic diagnosis of CIN1 with metaplasia.  All algorithms incorrectly classified 
this site as neoplastic (D) HRME image from a site with a histopathologic diagnosis of 
CIN3. It was correctly identified as high grade using the number of abnormal nuclei per 
unit area method and NC ratio method. It was incorrectly identified as non-neoplastic sby 
the fraction of nuclei that are abnormal method and by using median eccentricity and 
mean area.  
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 In future studies, HRME analysis should be streamlined.  First, the outline of 
the fiber should be determined automatically.  This proved to be difficult for this 
study because of the presence of debris on the fiber boundaries.  In future studies, a 
calibration image of a fluorescent target should be taken in order to define the fiber 
boundaries prior to in vivo imaging.  Additionally, a single image should be taken 
from each site of interest.  Taking movies at each location is not conducive to near 
real-time HRME analysis and diagnosis.  Furthermore, selection by an individual 
introduces a degree of unwanted variability to the analysis process.  After an image 
is acquired, Michelson contrast and mean intensity should be calculated to 
determine if the image acquired is of sufficient quality to be analyzed.  If not, the 
user should be prompted to take another image until an image of sufficient quality is 
obtained.  Increasing specificity may require more advanced image processing 
algorithms or an additional contrast agent.   
In the immediate future, either NC ratio or the number of abnormal nuclei 
per unit area should be used.  These algorithms both correctly identified 45 out of 
46 CIN3 sites as neoplastic.  Additionally, they both classified all ten cases of cancer 
as neoplastic.  These algorithms both depend directly on the automatically 
determined ROI.  It is important to continue to refine the ROI selection process to 
avoid selecting large areas where the fiber is not in contact with tissue or is 
occluded by debris.   
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 Chapter 5
Chapter 5: A mobile-phone based 
high-resolution microendoscope 
5.1. Introduction  
Cervical cancer remains a major global health concern with an estimated 
527,600 new cases and 265,700 deaths attributed to cervical cancer in 2012.  Nearly 
90% of all cervical cancer deaths occurred in developing countries1.  In countries 
with the financial and human resources to support national screening programs, the 
incidence and mortality of cervical cancer has dropped drastically 5.  Screening 
prevents cervical cancer by allowing for the detection and treatment of cervical 
precancer 5.  An effective vaccine has been developed against HPV 16 and 18 which 
together are responsible for an estimated 70% of cervical cancer cases68,71.  More 
recently, a 9-valent HPV vaccine has been developed which offers protection against 
oncogenic HPV strands responsible for approximately 90% of all cervical cancers73.  
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However, implementation in low resource settings is limited largely due to the high 
cost of the vaccine75.  Furthermore, the vaccine is not effective for women who are 
already infected with HPV.  Screening will continue to remain important for decades 
for those that did not receive the vaccine prior to infection and for those infected 
with oncogenic HPV types the vaccine does not protect against 74. Unfortunately, in 
low- to middle-income countries (LMICs) screening programs are difficult to 
implement due to a lack of human and financial resources and inadequate 
infrastructure33.  
Alternative, low-cost screening techniques appropriate for LMICs have been 
developed to decrease the global burden of cervical cancer.  Visual inspection with acetic acid ȋV)AȌ and visual inspection with Lugol’s iodine ȋV)L)Ȍ are two alternative 
screening techniques 33. In VIA, a clinician applies dilute acetic acid directly to the 
cervix and examines the cervix for signs of acetowhitening, a localized whitening of 
the epithelium associated with abnormal underlying tissue 39.  In VILI, dilute Lugol’s 
iodine is applied topically to the cervical epithelium, staining normal glycogen-rich 
squamous epithelium preferentially, leaving glycogen-depleted proliferative 
cancerous and precancerous lesions unstained45. More recently, human 
papillomavirus (HPV) DNA screening has been explored for cervical cancer 
screening.  HPV DNA testing is highly sensitive 101 because virtually every case of 
cervical cancer is caused by a persistent high-risk HPV infection 7. However, VIA, 
VILI and HPV DNA testing are all limited by high false-positive rates and low 
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positive-predictive values 45,49,89,102, leading to substantial overtreatment when used 
as part of a see-and-treat strategy.  
Various optical imaging techniques have also been explored to allow for 
identification of cervical precancer in vivo 53. One such technique is the high-
resolution microendoscopy 57,58,67.  The high-resolution microendoscope (HRME) is 
a fiber bundle-based fluorescence microscope capable of imaging cell nuclei in vivo.  
The HRME system is used following topical application of the fluorescent topical 
contrast agent proflavine, which selectively stains cell nuclei.  HRME images 
obtained with the device can be used to quantify nuclear features associated with 
neoplastic progression, such as nuclear-to-cytoplasmic ratio and nuclear 
eccentricity 60,66. In pilot studies in China 60 and Botswana 66, the HRME identified 
cervical pre-cancer with high sensitivity and specificity.  However, the high cost 
($5,000) and size (28cm x 23cm x 6.5cm) of the device preclude its use in some low-
resource settings.  The cost and size of the standard HRME are driven by three main 
components: a scientific-grade camera, a laptop and off-the-shelf optomechanics 
57,58. Recent advances in mobile phone technology, including high processor speeds 
and compact digital cameras, provide a unique opportunity to simultaneously 
reduce both the size and cost of the HRME.  Due to the ubiquity of mobile phones 
and their increasingly sophisticated cameras, other research groups have designed 
mobile phone-based microscopes 103,104.  Here, we report a low-cost, highly portable 
mobile HRME (mHRME) utilizing a mobile phone and custom 3D-printed parts in 
lieu of a scientific-grade camera, laptop and commercial optomechanics.   
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5.2. Materials and Methods 
5.2.1. Optical Design 
 The mHRME is a fiber-based fluorescence microscope, similar in 
operation to that described by  Muldoon et al. 57.  The mHRME consists of four main 
components: optical lenses and filters, a mobile phone, a light emitting diode (LED) 
light source and a one millimeter outer-diameter coherent fiber bundle.  The device 
was designed with a target magnification of 1.0 to ensure that the entire field-of-view ȋFOVȌ of the fiber fit within the dimension of the cell phone’s complementary 
metal-oxide-semiconductor (CMOS) sensor.  To minimize distortion, Steinheil lenses 
were selected for all of the imaging optics because they are optimized for 1:1 
conjugate ratios.  To create a compact, portable device, all lenses had a maximum 
diameter of no more than 12.5 mm.   ZEMAX was used to aid in commercial lens 
selection and positioning. 
An overview of the device’s optical pathway is shown in Figure 5-1A. An LED 
(LED Engin, LZ1-10DB00) provides excitation light centered at 460 nm.  The LED is 
powered in one of two ways.  For cell phones that offer USB on-the-go support, the 
LED is powered through a USB cable connected to the phone.  For phones lacking 
this capability, an external USB battery pack (e.g., Anker 10,000 mAh battery pack) 
may be used.  The current is regulated by a 1000 mAh LED driver (LED Supply, 
03023-D-E-1000P ).  The LED is collimated through an achromatic doublet (Edmund 
optics, 65-550) before passing through a 20 nm band-pass excitation filter centered 
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Figure 5-1: Schematic of mHRME. (A) Diagram of 
optical layout of the system. (B) Solidworks illustration 
depicting all components of the system. 
 
at 448 nm (Edmund Optics, 86-975).  The excitation light is then reflected towards 
the fiber bundle via a dichroic mirror with a 482 nm cut-on wavelength (Edmund 
86-317).    After 
reflecting off the 
dichroic mirror, the light 
is coupled to a fiber 
bundle (Fujikura,  FIGH-
30-850N) by a pair of 18 
mm effective focal 
length (EFL) triplet 
lenses (Edmund Optics, 
45-399).   The fiber 
bundle used here is 
composed of 30,000 fibers with Ͷ μm spacing 
between each fiber.  The 
dimensions of the fiber 
bundle also directly 
determine the field-of-
view of the system.   
The system is designed to be used with the fiber bundle placed in direct 
contact with proflavine-stained epithelial tissue.  Light emitted from the tissue is 
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then collected through the same fiber.  After passing through the fiber, emission 
light is collected through the pair of triplet lenses prior to transmitting through the 
dichroic mirror.  Next, the emitted light is filtered by a 515 nm long-pass color glass 
emission filter (Schott OG-515).  The remaining signal is redirected with an 
aluminum mirror (Thorlabs ME05S-G01) through a 25mm EFL triplet lens (47-675 
Thorlabs) and it is coupled to the cell phone’s lens through a ͳʹ.ͷ mm EFL triplet.  
Based on the optimal lens positions identified in ZEMAX, the cell-phone 
attachment and optomechanic holder was printed with a 3D printer (3D systems, 
South Carolina).  The 3D-printed structure consists of individual pieces that snap 
together as shown in Figure 5-1B.  The pieces contain cutouts corresponding to the 
exact size of the lenses, ensuring that the lenses are positioned accurately and 
precisely.  After assembly, four threaded aluminum rods are placed in through-holes 
to ensure stability during use.   The optical system connects directly to the phone, 
thereby ensuring alignment of the optics with the mobile phone camera.  We tested 
the mHRME using two phones:  the Samsung Galaxy Note 3, which features 13 a 
megapixel camera and 2.3 GHz processor and an HTC One X+, an older, midlevel 
international smartphone with 8 megapixel resolution.   
5.2.2. Imaging Testing 
5.2.2.1. In Vitro Imaging 
We first determined the resolution of the system using a standard Air Force 
Resolution Target.  To validate the ability of the mHRME to image cell nuclei and to 
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assess the signal-to-background ratio (SBR) we evaluated its performance in cultured (eLa cells. (eLa cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) in a 150 mm Petri dish until approximately 50% confluent.  The media was 
aspirated and the cells were washed once with phosphate buffered saline (PBS).   
After aspirating the PBS, 1 mL of 0.01% proflavine in PBS was applied to cover the 
cells.  After one minute, the proflavine was removed and cells were washed twice 
with PBS.  The cells remained in PBS solution and were imaged with the mHRME 
system directly in the Petri dish; the tip of the fiber was placed in direct contact with 
the cells.    
5.2.2.2. In Vivo Imaging  
After successfully imaging cultured cells, we proceeded to test the mHRME in 
vivo. Patients with abnormal Pap smears in the state of Sao Paulo, Brazil referred to 
Hospital de Câncer de Barretos for colposcopy were enrolled in a pilot study to 
evaluate the efficacy of the standard HRME in discriminating between non-
neoplastic and neoplastic lesions100.  The National Committee for Ethics in Research 
(CONEP) of Brazil and the Institutional Review Boards from Hospital de Câncer de 
Barretos, MD Anderson Cancer Center and Rice University approved this study.   A 
subset of the patients in this study was also imaged with our mHRME to assess its in 
vivo imaging capabilities.  
During routine colposcopy, the clinician first evaluated the cervix using 5% 
acetic acid under white-light conditions.  If an abnormal region was observed, the 
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clinician then applied .01% (w/v) proflavine solution to the cervix using a spray bottle and cotton swab. After the application of proflavine, Lugols’ iodine was 
applied as part of the standard of care for colposcopy at Hospital de Câncer de 
Barretos .  Proflavine was then applied again to enhance signal strength.  Next, the 
clinician placed the tip of the mHRME probe in gentle contact with an area of the 
cervix that appeared normal by colposcopy.  Images were captured using the 
android app Camera FV-5 (FGAE studios, Stuttgart, Germany).  The software 
contrast preset was set to a maximum value of 10 for all images.  After acquiring 
images of normal squamous epithelium, mHRME images were collected from a 
colposcopically abnormal lesion.  
5.3. Results  
5.3.1.  System Characterization  
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The key properties of the system are outlined in Table 3-1.  The device, 
excluding the mobile phone, weighs 170 g and is 15 cm x 7 cm x 8 cm using the 
Galaxy Note 3.   The power output at the distal end of the fiber is 0.8 mW/cm2 and 
the field-of-view is 750 µm.  The system is capable of resolving element five of group 
six, as shown in Figure 5-2 using both the Galaxy Note 3 and HTC One X+; this 
element corresponds to a line-width of 4.9 μm. 
 Standard HRME mHRME – Galaxy Note 3 mHMRE – HTC One X+ 
Image Sensor Size 
(diagonal) 
11 mm  5.87 mm 5.68 mm 
Spatial Resolution 4.4 µm 4.9 µm 4.9 µm 
Fiber Bundle Size 30,000 fiber cores 30,000 fiber cores 30,000 fiber cores 
Pixels per fiber 27 pixels 20.7 pixels 9.8 pixels 
Field-of-View 750 µm 750 µm 750 µm 
Weight* 2500 g 170 g 170 g  
Dimensions 28 cm x 23 cm x 6.5 cm 15 cm x 7 cm x 8 cm 13 cm x 7 cm x 8 cm 
Prototype Cost $5,500 $1,650 $1,350 
Table 5-1 Key system parameters for the standard HRME and mHRME using the Galaxy Note 3 
and HTC One X+.  Both mHRMEs are significantly smaller, lighter and less expensive than the 
standard HRME system. *Weight excludes the weight of the laptop or mobile phone 
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5.3.2. Cultured Cell Imaging  
 
Figure 5-2: System resolution evaluation.  Air-Force Resolution Target image taken with the 
mHRME system using (A) the Galaxy Note 3 and (B) The HTC One X+   The smallest target the 
system can resolve is group 6, element 5 (boxed) corresponding to a resolution of 4.9 µm 
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Image
s of 
proflavine-
stained HeLa 
cells taken 
with the 
Galaxy Note 3 
and HTC One 
X+ are shown 
in Figure 
5-3.  The 
figure shows 
the green 
channel from an otherwise unprocessed mHRME image.  In order to evaluate the 
signal-to-background ratio, the cells were segmented automatically from the 
background using a custom MATLAB script.  First, a top hat filter was applied reduce 
the background and correct any uneven illumination.  Next, a threshold was 
determined using Otsu’s method 95 to separate nuclei from the background of the 
image.  The resulting segmentation corresponding is shown in Figure 5-3.  The 
signal-to-background ratio was calculated by dividing the mean intensity of pixels 
within the segmented cell nuclei by the mean intensity of pixels within the fiber 
bundle not classified as nuclei.   The resulting signal-to-background ratio is 5.3 for 
 
Figure 5-3 HeLa cell imaging.  Raw images of cultured HeLa cells 
taken with the (A) Galaxy Note 3 and (B) HTC One X+  mobile high-
resolution microendoscopes.  Nuclei from (A)  and (B) are 
automatically selected from the background and outlined in (C) 
and (D), respectively.   
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the Galaxy Note 3 system and 4.4 for the HTC One X+ system, comparing favorably 
to that obtained with previous standard HRME systems 57,67.  
 
5.3.3. In Vivo Imaging   
The mHRME was tested by colposcopists at Hospital de Câncer de Barretos to 
determine its ability to image squamous epithelium in vivo.  Figure 5-4 shows the 
completed prototype with the Galaxy Note 3 and a photograph of the mHRME in the 
colposcopy clinic prior to in vivo use.  Figure 5-5 provides representative in vivo 
mHRME images obtained from colposcopically normal and colposcopically 
abnormal squamous epithelium.  The mHRME image of colposcopically normal 
 
Figure 5-4 Photographs of the mHRME prototype. (A) Photograph of the 
completed mHRME Galaxy Note 3 prototype. (B) Photograph of the mHRME in a 
coloposcopy clinic at Hospital de Câncer de Barretos. 
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Figure 5-5 In Vivo imaging of the cervix with the mHRME of (A) normal 
squamous epithelium and (B) high grade dysplasia. The white circle indicates the 
boundary of the fiber bundle.  The red arrows in (B) indicate the junction between 
the lesion and surrounding normal tissue 
 
tissue, shown in Figure 5-5A shows round, well-spaced and small nuclei, consistent 
with the histological diagnosis of normal squamous epithelium.  In contrast, the 
majority of the mHRME image of colposcopically abnormal tissue, shown in Figure 
5-5B shows large, pleomorphic, crowded nuclei, consistent with the histological 
diagnosis of high grade dysplasia.  This image was taken at the edge of a lesion; the 
junction between abnormal and normal epithelium is evident in the bottom left 
hand region of Figure 5B and is marked with arrows.  Both mHRME images in 
Figure 5-5 have been post-processed identically by selecting only the green 
channel, applying a top hat filter, and enhancing the contrast.  In the future, this 
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post-processing could be achieved in near real-time with a custom android camera 
application.  
5.4. Discussion 
We developed a mobile phone high-resolution microendoscope capable of 
imaging epithelial cells in vivo.  At 4.9 µm, the resolution is slightly inferior to that of 
the standard HRME system (4.4 µm), likely due to the lower quality, smaller camera 
sensor.  However, the resolution is sufficient to acquire sub-cellular resolution 
images of cervical tissue in vivo.  Using a mobile phone eliminates the need for a 
scientific-grade camera and laptop, thereby significantly reducing both size and cost.   
The battery powered system can be used in settings without wall electricity.  Using the Galaxy Note ͵’s built-in battery provides two hours of imaging, while the 
economical(~$30) Anker external USB battery pack allows for ten hours of imaging.   
System cost could be reduced substantially if produced in large quantities.  
First, 3D printed components could be made by injection molding, at a fraction of 
the price.  Second, the optical lenses and LEDs drop markedly in price when 
purchased in bulk.  With large-scale production the price of the mHRME would be 
under $500, exclusive of the cell phone.  Because the device does not have any 
associated consumables, we believe this price target is reasonable even for use in 
low-resource settings.   
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The device is also designed to be flexible to allow for different applications.  
The LED, filters and dichroic mirror can be changed in order to utilize other 
fluorescent dyes without any additional system modifications.  The field-of-view can 
be changed depending on the application by using different fiber bundles.    For 
applications in which a much larger field-of-view is desirable, mosaicking 
approaches can be implemented99.  Finally, the optics of the system are designed to 
interface with a variety of mobile phones.  The magnification was chosen such that 
the CMOS is underfilled.  This ensures that if other mobile phones were selected 
with smaller sensor sizes, the fiber image would still fit on the sensor.  The mHRME 
sends a collimated signal to the cell phone camera.  A cell phone with a camera of at 
least 8 megapixels that can be set to infinity or landscape mode is sufficient to 
acquire in-focus images with subcellular resolution.   
In conclusion, we have demonstrated a mobile phone based microscope 
capable of achieving sub-cellular resolution in vivo.  While initial results are 
promising, further studies are necessary to validate that the device can identify 
cervical precancer with high sensitivity and specificity to evaluate its diagnostic 
performance.  Advances in mobile phone technology and rapid prototyping 
techniques present an exciting opportunity to develop new diagnostic imaging 
techniques tailored for use in low-resource settings.  We believe this device may 
have particular utility in countries in which traditional cervical cancer screening 
techniques are difficult to implement.   
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 Chapter 6
Chapter 6: Highly Sensitive Two-
Dimensional Paper Network 
Incorporating Biotin-Streptavidin for 
the Detection of Malaria++ 
6.1. Introduction  
Microfluidic paper-based devices are a novel class of point-of-care rapid diagnostic test ȋRDTȌ capitalizing on paper’s low cost, ubiquity, and wicking 
properties78.  A subset of microfluidic paper-based devices, lateral flow tests (LFTs), 
are a staple of clinical point-of-care (POC) diagnostics due to their simplicity, speed 
and low cost105.  LFTs are typically simple sandwich immunoassays designed to 
                                                        
 
++ This chapter has been published in Grant BD, Smith CA, Karvonen K, Richards-Kortum R. 
Highly Sensitive Two-Dimensional Paper Network Incorporating Biotin–Streptavidin for the 
Detection of Malaria. Anal Chem [Internet] 2016;88(5):2553–7130. 
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detect proteins of clinical importance.  They often have higher limits-of-detection 
than their conventional enzyme linked immunoassay (ELISA) counterparts, 
reducing their clinical utility81,106.  Increased sensitivity requires the ability to 
implement more complicated, multistep assays, i.e. utilizing chemical amplification 
techniques.  Recently, two dimensional paper networks (2DPN) have been 
developed to expand the utility of traditional LFTs106.  These 2DPNs provide the 
ability to run multistep immunoassays with minimal user interaction and do not 
require additional instruments or significantly increase cost106.  These devices allow 
for the inclusion of strategies which improve the limit-of-detection (LOD) relative to ǲone-dimensionalǳ LFTS81–85,106, providing the means to develop highly sensitive 
POC assays for clinically relevant targets.     
One potential application of highly sensitive RDTs is the diagnosis of malaria.  The World (ealth Organization ȋW(OȌ reports that half the world’s population is at 
risk for malaria107.  Malaria causes an estimated 627,000 deaths annually with 90% 
occurring in sub-Saharan Africa107.   Most of these deaths result from infections with 
the Plasmodium falciparum (Pf) parasite, making its detection particularly 
important108.  RDTs that diagnose Pf malaria often target the Pf histidine-rich 
protein 2 (Pf HRP2), an antigen released by blood stages of Pf parasites109.  Using 
traditional ELISA techniques, researchers have been able to reliably measure Pf 
HRP2 levels as low as 0.11 ng/mL86, corresponding to approximately 0.7 
parasites/µL, using the maximum circulating approximation developed by Marquart 
et al110.  In contrast, traditional lateral flow RDTs for Pf HRP2 are able to achieve 
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limits-of-detection as low as 6.94 ng/mL (8 parasites/µL)83,110.  Fu et al. 
demonstrated that by implementing a 2DPN gold enhancement immunoassay, they 
could achieve a limit-of-detection of 2.9 ng/mL (4 parasites/µL)82,110.  While a 
significant improvement, additional steps are necessary to achieve a LOD 
comparable to the best reported traditional ELISAs. Malaria elimination programs, 
which aim to detect subclinical malaria infections, require low LODs equivalent to 
standard HRP2 ELISAs111. 
Incorporating a streptavidin-biotin detection system can improve the limit-
of-detection of immunoassays. Streptavidin-biotin detection strategies have been 
used for decades in ELISAs due to their many advantages112.  Briefly, streptavidin 
has an extremely high affinity for biotin113 (Kd ~ 4 x 10-14), streptavidin binds to 
biotin with high specificity, and biotin is small (244 Da) allowing it to be readily 
covalently linked to molecules without altering biological activity112.  Streptavidin is 
available with a variety of detection labels that produce additional amplification, 
including the enzyme horse-radish peroxidase112, enabling the detection of 
biotinylated molecules.  Furthermore, streptavidin-biotin detection strategies offer 
an inherently amplified signal versus direct detection strategies because 
streptavidin and biotin both provide four binding sites for one another112. 
Additional sensitivity can be achieved by utilizing streptavidin conjugated to 
polymers of horse-radish peroxidase, providing a larger number of enzyme 
molecules per bound molecule.  Here we demonstrate that by using a larger sample 
size than previously reported 2DPN RDTs and employing a streptavidin poly- horse-
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Figure 6-1 : Device diagram.  (A) Device prior to folding with key components 
labeled.  (B) Device folded to initiate flow with reagents and test area highlighted.   
 
radish peroxidase detection comparable to the lowest reported limit-of-detection by 
traditional ELISA. 
6.2. Materials and Methods 
6.2.1. Two-Dimensional Paper Network Device  
The two-dimensional paper network (2DPN) devices, depicted in Figure 6-1,  
are constructed on a plastic backbone consisting of 10 mil Dura-Lar (Blick Art 
Supplies, Galesburg, Illinois) and 5 mil adhesive-backed Dura-Lar (Blick Art 
Supplies, Galesburg, Illinois).  The five reagent storage and release pads and the 
sample pad are cut from glass fiber pads (grade 8951, Ahlstrom, Helsinki, Finland).  
The wicking pad is made from cellulose (C083, Millipore, Billerica, MA).  The 
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Figure 6-2: Flow profile comparison between devices.  Food coloring was 
used to compare the flow between two device designs.  The linear device 
showed consistently sequential reagent delivery, while the leg device showed 
parallel reagent flow at the 25, 50 and 80 minute time points. 
primary lateral flow channel consists of 4 mil backed high flow nitrocellulose 
(HF135, Millipore, Billerica, MA).  All materials were cut using a CO2 laser cutter 
(Universal Laser Systems, Scottsdale, Arizona).   
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6.2.2. Sequential Fluid Flow Experiment 
We performed experiments to evaluate the flow of reagents in two different 
2DPNs designed to deliver six reagents sequentially.  The first device was modeled 
after the device described by Fu et al82.  Reagent pads were placed on ǲlegsǳ 
extending at a ninety-degree angle off the main lateral flow body (Figure 6-2).  This device is referred to as the ǲleg designǳ in the remainder of this manuscript. The 
second device consists of the same reagent pads placed directly on the main body of 
the device.  Due to the fact that this device consists of a linear piece of nitrocellulose, it is referred to as the ǲlinear deviceǳ.   
 In order to visualize the flow of reagents, we used food dye (McCormick, 
Sparks, Maryland) diluted in Phosphate Buffered Saline (PBS) with .05% Tween® 
20 (PBST).   Glass fiber pads with capacities of 50 µL, 15 µL, 20 µL, 25 µL, 30 µL and 
35 µL were placed in their respective positions on the device.  Different colors of 
food coloring, diluted in PBST, were dispensed with the appropriate volume on each 
pad, as shown in Figure 6-1.  The device was folded in half to initiate fluid flow.  
Images were acquired with a flatbed scanner at 600 dots-per-inch (DPI) at 15, 25, 
40, 50, 60 and 80 minutes after flow initiation. 
6.2.3. Pf HRP2 2DPN Assay Preparation 
Prior to device assembly, we pipetted 0.4 µL of the capture antibody, a 
murine antibody to Pf HRP2 (Immunology Consultants Laboratory, Portland, OR), 
directly onto the nitrocellulose strip at the test location. The strip was allowed to 
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dry for ten minutes before applying another 0.4 µL of antibody to the same spot.  It 
was then dried for 90 minutes at ͵͹ ˚C.  
To prevent nonspecific binding, the nitrocellulose strip was blocked in a 
similar fashion to that described by Fu et al.82.  The device was completely 
submerged for twenty minutes in PBS containing 5% sucrose, 2% bovine serum 
albumin (BSA), 0.25% PVP (40KD mW, Sigma Aldrich, St. Louis, Missouri), and .05% Tween ʹͲ.  The nitrocellulose was dried for ͸Ͳ minutes at ͵͹˚C before completely 
assembling the device.  Finally, the device was assembled as shown in Figure 6-1.  
The unconjugated murine detection antibody (Immunology Consultants 
Laboratory, Portland, OR) was conjugated to biotin using EZ-link biotinylation kit 
(Thermo Fisher Scientific, Waltham, Massachusetts).  The biotin conjugated 
detection antibody was desalted using Zeba columns (Thermo Fisher Scientific, 
Waltham, Massachusetts) to remove any unbound biotin.  A streptavidin- horse-
radish peroxidase polymer consisting of 400 horse-radish peroxidase monomer 
molecules (poly-HRP80, Fitzgerald, Acton, Massachusetts) was used as the 
secondary detection mechanism.  Diaminobenzidine (Sigma-Aldrich, St. Louis, 
Missouri) served as the colorimetric substrate.    
6.2.4. Running the 2DPN Assay 
The biotinylated detection antibody was diluted to 40 µg/mL in PBST.  The 
streptavidin-horse-radish peroxidase polymer was diluted to 8 µg/mL in PBST.  
DAB was dissolved in Millipore water at a concentration of 0.5 mg/mL.  Samples 
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were created by spiking recombinant Pf HRP2 (CTK Biotech, San Diego, CA) in fetal 
bovine serum (FBS).  We tested concentrations of 0, 0.1 ng/mL, 0.25 ng/mL, 0.5 
ng/mL, 1 ng/mL Pf HRP2 in triplicate on both the linear and leg 2DPNs.  
Immediately prior to running the assay, sodium percarbonate (Sigma-Aldrich, St. 
Louis, Missouri) was added to the DAB solution to a concentration of 5.7 mg/mL.  
Sodium percarbonate provides the necessary hydrogen peroxide for the DAB 
colorimetric reaction to occur. 
To run the assay, 50 µL of sample was pipetted onto the first pad.  Next, 15 µL 
detection antibody was applied to the second pad, followed by 20 µL streptavidin-
horse-radish peroxidase, 25 µL PBST, 30 µL DAB-sodium percarbonate solution, and 
35 µL PBST.  The device was then folded in half to initiate fluid flow.  Each device 
was scanned in black and white at 600 DPI using a flatbed scanner at 60 minutes 
and 90 minutes after assay initiation.   
6.2.5. Running Standard ELISA Kit 
We also tested all spiked FBS samples using the Malaria Ag CELISA (Cellabs, 
Sydney, Australia). We additionally tested 0.05 ng/mL of HRP2 spiked in FBS with 
the CELISA.  The CELISA is the primary commercialized HRP2 ELISA111 and has 
reported sensitivity and specificity equivalent to quantitative polymerase chain 
reaction (qPCR) in symptomatic patients114.  
The assay was run in accordance with the provided protocol.  Briefly, 100 µL 
spiked FBS sample was added into each well and incubated for one hour at room 
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temperature in a humid chamber.  The wells were manually washed five times with 
300 µL PBST. Next, 100 µL of detection antibody was added to each well, and the 
plate was incubated for 1 hour at room temperature in a humid chamber.  After 
incubation, the wells were washed another five times with 300 µL PBST. Finally, 100 
µL of substrate was added to each well, and the plate was incubated in the dark at 
room temperature for fifteen minutes. 50 µL of stop solution was added to each 
well, and the plate was imaged at 450 nm using a plate reader (Tecan, Zürich, 
Switzerland). A two-sided t-test was used to test for significant differences in mean 
absorbance between different HRP2 concentrations. P-values of less than 0.05 were 
considered significant.  
6.2.6. Analysis of 2DPN Assay Signal  
A fixed size rectangular region of interest (ROI) was placed at the capture 
region of each image.  An additional background ROI of identical size was selected 
automatically halfway between the signal ROI and the wicking pad.  To determine 
the signal, the complement of the image was first computed such that higher pixel 
intensity corresponded to a higher signal.  The test signal was defined by calculating 
the mean of the maximum pixel intensity for each row of the test ROI.  The 
background signal was calculated identically using the background ROI.  Finally, the 
test ROI signal was divided by the background ROI signal to determine a signal-to-
background ratio.  A two-sided t-test assuming unequal variances was used to test 
whether differences in the signal-to-background ratio for different antigen 
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concentrations were statistically significant; p-values of less than 0.05 were 
considered significant. 
6.3. Results and discussion 
6.3.1. Sequential Flow Comparison 
The flow comparison between the leg and linear is shown in Figure 6-2.  An 
image of each device is shown immediately after folding.  Additional images of the 
test zone of each device are shown at various time points after folding to assess 
flow.  In both devices, the final reagent reached the test zone in 80 minutes.  
However, the leg device resulted in parallel flow of consecutive reagents as opposed 
to sequential reagent delivery. This is particularly apparent at the 25, 50 and 80-
minute time points.  Conversely, the linear device shows consistent sequential 
reagent delivery at all time points.  
 Results suggest that the nitrocellulose inlets of the leg device, which are 
perpendicular to fluid flow, disrupt the desired sequential laminar flow.  This effect 
is exacerbated relative to previously published 2DPNs by having a larger sample 
pad.  In previously published devices, each sequential reagent pad is designed to 
hold a larger volume than the previous pad81–85,106.  By placing the largest pad first, 
we introduced a strong force perpendicular to the desired flow immediately prior to 
the test area.  Furthermore, we extended the total number of reagent pads.  This 
increases the number of inlets perpendicular to the device, further exacerbating the 
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effect.  The linear device solves this challenge by placing reagent pads symmetrically 
centered on the device, resulting in no net force perpendicular to the primary 
nitrocellulose channel.   
6.3.2. Pf HRP2 Assay 
Example images for 0.5 ng/mL, 0.1 ng/mL and 0 ng/mL HRP2 concentrations 
are provided for both the linear and leg devices in Figure 6-3  In Figure 6-3G, the 
signal ROI is outlined in a solid black box and the background ROI in the dotted 
black box.  Figure 6-3 also shows a scatter plot of the calculated signal-to-
background ratios for concentrations ranging from 0 to 1 ng/mL with their standard 
deviations for both linear and leg devices. For the linear 2DPN, at 60 minutes, the 
mean SBR between 0 ng/mL and 0.1 ng/mL were not statistically different.  The SBR 
between 0.5 ng/mL and 0.25 ng/mL were also not statistically different.  The mean 
SBR for all other concentrations were significantly different at 60 minutes for the 
linear 2DPN. At 90 minutes, the mean SBR for all antigen concentrations were 
significantly different from one another for the linear 2DPN.  For the leg 2DPN, there 
were no significant differences in mean SBR between HRP2 concentrations at 60 or 
90 minutes. Although signal was present for 0.5 ng/mL and 1.0 ng/mL after 90 
minutes, the large variability in SBR prevented differences from reaching statistical 
significance. We believe the inferior performance for the leg device is due to the 
parallel reagent delivery illustrated with the food coloring experiments. When signal 
is present for the leg device, it is only present in the middle of the test zone as 
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shown in Figure 6-3D.  This is likely the only location where all reagents are 
delivered in sufficient quantity.  
 
Figure 6-3 : Results of Pf HRP2 assay. Representative scanned image for the linear 
device of (A) 0.5 ng/mL Pf HRP2. (B) 0.1 ng/mL and (C) 0 ng/mL after 90 minutes.  
Representative scanned images for the leg device are shown in (D), (E) and (F) for 
the same concentrations. (G) Signal and background regions-of-interest.  The solid 
black box corresponds to the signal region-of-interest and the dotted black box to 
the background region-of-interest. (H) A plot of the signal-to-background ratio for 
the leg 2DPN for concentrations ranging from 0 to 1 ng/mL Pf HRP2 at 60 and 90 
minutes after assay initiation. Each data point corresponds to the average of three 
separate tests. There is no significant difference in mean SBR between any antigen 
concentration at 60 or 90 minutes.  (J) Presents the same plot for the linear 2DPN. At 
60 minutes, there is no significant difference between 0.1 ng/mL and 0 ng/mL or 
between 0.5 ng/mL and 0.25 ng/mL.  The mean SBR is significantly different 
between all other antigen concentrations. At 90 minutes, the mean SBR is 
significantly different between all antigen concentrations for the linear device.  
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 For the CELISA kit, there was no significant difference between the mean 
absorbance for 0.05 ng/mL and 0 ng/mL.  Mean absorbance were significantly 
different between all other concentrations.    The LOD for the linear device at 90 
minutes is 0.1 ng/mL, comparable to the lowest reported ELISA LOD of 0.11 
ng/mL86, corresponding to approximately 0.7 parasites/µL110.  The CELISA HRP2 
ELISA kit used here also produced a LOD of 0.1 ng/mL.  Results using this kit are 
shown in Figure 6-4.  
The improvement in limit-of-detection is due to both the use of polymerized 
horse-radish peroxidase conjugated streptavidin in tandem with a biotinylated 
detection antibody and the 50 µL sample size.  Ramachandran et al. reported a 2DPN 
achieving a LOD of 6.5 ng/mL using 10 µL of spiked FBS sample employing the same 
capture and detection antibody and the same colorimetric substrate reported 
here85.   Increasing the sample size would have maximally improved the LOD to 1.3 
ng/mL.  The additional improvement in limit-of-detection is attributable to the 
streptavidin-biotin detection system.  A 50 µL plasma sample size is obtainable from 
a finger prick using a high-flow lancet, e.g. the BD Microtainer Contact-Activated 
Blue Lancet which provides up to 500 µL of blood per single puncture115.   
 
6.4. Conclusions 
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We have demonstrated an extended 2DPN capable of delivering the sample 
and five reagents sequentially with a limit-of-detection equivalent to the Cellabs 
CELISA Malaria Antigen Kit.  Improvements for this device could be made by 
incorporating dry reagent storage83,85 and a plasma separating membrane, allowing 
for whole blood analysis.   Because of the ease of biotinylation, the device can be 
readily modified for the detection of other antigens that require a highly sensitive 
point-of-care test. The improvement LOD comes at the cost of increased assay time.  
However, for assays in which clinically necessary LOD cannot be achieved by 
conventional lateral flow tests, this method offers a novel point-of-care strategy.  
  
 
Figure 6-4: Results of Pf HRP2 CELISA kit. A plot of the Pf HRP2 CELISA for 
sample concentrations ranging from 0 to 1 ng/mL run in triplicate Error bars 
represent one standard deviation. There is a significant difference (p<0.05) 
between all concentrations except between 0.05 ng/mL and 0 ng/mL.   
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 Chapter 7
Chapter 7: A paper-based HPV VLP 
immunoassay for determining HPV 
vaccination status 
7.1. Introduction 
More than 520,000 new cases of cervical cancer and 265,000 related deaths 
occur annually 1. Over  85% of cases of and deaths due to cervical cancer occur in 
low- and middle-income countries (LMICs), where cervical cancer is the third 
leading cause of cancer death among women1. LMICs bear a disproportional burden 
of cervical cancer primary due to the difficulty of implementing prevention and 
screening programs in these locations 33.  Infection with the human papillomavirus 
(HPV)  is the cause of virtually all cases of cervical cancer 7; globally, HPV16 and 
HPV18 are responsible for 70% of cervical invasive squamous cell carcinoma of the 
cervix 116.    Vaccines to prevent HPV infection have the potential to drastically 
 92 
 
reduce the global burden of cervical cancer 70.  Three HPV vaccines, Cervarix, 
Gardasil, and Gardasil-9, are commercially available to protect against HPV16 and 
HPV18 68,70,117.  Gardasil also protects against HPV 6 and HPV11 which cause 90% of 
genital warts 69.  Randomized, prospective studies have demonstrated the efficacy of 
Cervarix and Gardasil to preventing HPV16 and HPV18 infections, and HPV16- or 
HPV18-related cervical intraepithelial neoplasia (CIN) 69–71.  More recently a 
nonavalent vaccine, Gardasil-9, was developed that provides protection against  
nine HPV types including 6, 11, 16 and 18 and five additional oncogenic HPV types 
(31, 33, 45, 52 and 58)73.  Together these HPV types  cause 90% of all cervical 
cancer, thus mass immunization with Gardasil-9 may potentially prevent 90% of 
cervical cancers 73.  
Wide-scale adoption of HPV vaccines is predicted to significantly lower the 
incidence of cervical cancer worldwide, and reduce global disparities in cervical 
cancer incidence 117. The cost of the three-dose HPV series is approximately $390 
for the Cervarix Vaccine, $480 for Gardasil and $530 for Gardasil-9118.   Cost is the 
biggest barrier to national implementation of the HPV vaccine in LMICs 75.  Recent 
studies suggest that two doses of vaccine may provide protective immunity 119,120 
and be more cost-effective than the three-dose series 121.    Lack of comprehensive 
medical records in LMICs 122 presents another challenge to national HPV 
immunization programs.    Absent medical records, providers must rely on patient 
self-reporting to assess whether a patient has received all recommended doses of 
vaccine. This can lead to vaccination of individuals who have previously received 
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sufficient doses of the vaccine.  In order to optimize cost-effectiveness, it is critical 
that vaccines are provided only to those who have not received the full series of the 
vaccine.   The accuracy of self-reported vaccine history varies depending on the 
vaccine 123. HPV vaccine self-reporting is particularly poor due to the multiple dose 
requirements.  A study evaluating the accuracy of self-reported of HPV vaccination 
history among adolescents revealed major inaccuracies 2.  Only 54% (36/66) of 
those who had received at least one vaccine correctly reported having had the 
vaccine and only 35% (17/48) of those who had received all three vaccines 
correctly self-reported having all three doses 2.  Due to the under-reporting of HPV 
vaccine status and the lack of reliable medical records in many developing countries, 
there is a significant possibility of unnecessary revaccination.   
HPV immunization status can be determined by measuring the serum 
concentration of HPV antibodies  Currently, serum HPV antibody concentration can 
only be measured using a virus like particle (VLP) enzyme-linked immunosorbent 
assay (ELISA) or a neutralization assay 77.  However, both of these assays 
traditionally require sophisticated laboratory equipment and highly trained 
personnel.   Low-cost, point-of-care alternatives to these tests are needed to help 
assess whether patients have previously received 2 or more doses of HPV vaccine in 
order to facilitate efficient vaccination programs.  Recently, Fu et al. reported 
instrument-free two-dimensional paper networks (2DPNs) to perform multistep 
immunoassays at the point-of-care82.  In this paper, we build on this approach to 
develop an equipment-free rapid paper immunoassay to detect antibodies to HPV-
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16 from a finger prick sample of capillary blood to rapidly determine HPV 
immunization status at the point-of-care. We report results from a pilot study of 28 
subjects to evaluate the whether an individual has received two or more doses of 
the Gardasil or Cervarix vaccines.  
7.2. Methods 
Figure 7-1 shows a photograph of the two-dimensional lateral flow assay to 
detect HPV antibodies from a drop of capillary blood.  An important design 
consideration is to discriminate between vaccinated individuals and individuals 
with a history of PHV infection.  The assay is designed to detect HPV16 antibodies 
because of the significantly higher HPV16 antibody geometric mean titers seen in  
vaccinated individuals relative to those with a history of natural HPV16 infection 124.   
This difference is much greater for HPV16 than for HPV18 124.  The assay consists of 
a lateral flow strip with three capture zones to capture HPV16 antibodies from the 
serum and a positive control zone.  HPV16 L1 virus like particles (VLPs) are 
immobilized at the capture zones and human immunoglobin (IgG) is immobilized at 
the positive control zone.  Three test zones were included to aid in discrimination 
between vaccinated individuals and those with a history of natural HPV infection. 
Preliminary tests were performed with pooled serum from individuals with a 
history of HPV16 infection (provided by the National Institute of Biological Safety 
and Controls) and serum from an individual who had received three doses of the 
Gardasil vaccine. These tests revealed using a single test zone did not allow for 
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visual discrimination between serum from an individual with a natural HPV16 
infection and one who had received three HPV vaccines. However, by using three 
test zones a difference was visually apparent (data not shown).  
 As shown in Figure 7-1A, the device consists of a nitrocellulose membrane 
with HPV16 VLPs immobilized at three test zones and human IgG immobilized at the 
positive control zone, a cellulose picking pad, a plasma separation membrane (right 
side) and three glad fiber pads, one of which contains dried detection antibody (left 
side) all adhered to a thin acetate sheet.   On the right side of the device, the plasma 
separation membrane is connected via a nitrocellulose leg to the main lateral flow 
strip.  On the left side of the device, three glass fiber pads are placed on exposed 
adhesive.  The middle pad contains dried anti-Human IgG conjugated to colloidal 
gold.  The device is operated by placing a blood sample on the plasma separation 
membrane and rehydrating the three glass fiber pads with buffer (PBST).  The 
plasma separation membrane allows the plasma to pass on to the nitrocellulose 
strip but retains red blood cells.  The adhesive cover is removed from the left side of 
the device.  Once the plasma reaches the plasma separation line, shown in Figure 
7-1A , the device is folded in half along the midline.  This places the glass fiber pads 
in direct contact with the main lateral flow strip and initiates sequential flow of the 
first wash buffer, labeled detection antibody and final wash buffer.  
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7.2.1. Production of HPV16 L1 virus-like particles    
HPV16 L1 virus-like-particles were produced by transfecting 293TT cells 
with a plasmid expressing codon-modified HPV16L1 (p16L1h) gene125.  The plasmid 
was supplied from Dr. Susanna Pang from the National Cancer Institute Laboratory 
of Cellular Oncology.  The methods to produce human papillomavirus pseudoviruses 
have been published in detail previously 126–129.   
Twenty-four hours prior to transfection, 2 x 107 293TT cells (National Cancer 
Institute Laboratory of Cellular Oncology) were plated on a 225cm2 flask in 50 mL of Dulbecco’s Modified Eagle Medium ȋDMEMȌ with ͳͲ% fetal bovine serum, ͳ% non-
essential amino acids and 1% Glutamax-I (Thermo Fisher Scientific).  Immediately 
prior to transfection, 112.5 µg p16l1h DNA was added to 5.6 mL Opti-MEM (Thermo 
Fisher Scientific) and in a separate tube 247.5 µL of Lipofectamine 2000 (Thermo 
Fisher Scientific) was added to 5.6 mL of Opti-MEM. The solutions were incubated 
separately for 10 minutes at room temperature and then combined.  After gentle 
mixing the combined solution was incubated for 20 minutes and then added directly to the cultured cells. The cells were transfected for Ͷͺ hours at ͵͹˚C before 
harvesting. 
Cells were collected, centrifuged and placed in a siliconized 1.5 mL tube.   Cells were lysed by resuspension in  Dulbecco’s phosphate buffered saline with 
calcium and magnesium (DPBS, Thermo Fisher Scientific) with 2.5% of 1 M 
ammonium sulfate, 0.5% Triton X-100 (Thermo Fisher Scientific), 0.1% Benzonase 
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(Sigma) and 0.1% Plasmid safe (Epicentre).  The lysis was then incubated overnight at ͵͹˚C to allow for capsid maturation.  The following day, the solution was adjusted 
to 0.8 M NaCl and incubated on ice for 10 minutes. The salt lysate was double-
clarified by centrifugation at 5,000 x g for five minutes.  Capsids were purified by 
ultracentrifugation with an Optiprep gradient126.  SDS-PAGE gels were run on each 
gradient fraction to determine if the fraction contained a significant amount of L1.  
Fractions containing L1 were pooled for use in the HPV antibody immunoassay.  
7.2.2. Fabrication of paper-based HPV VLP immunoassay 
All materials for the paper-based HPV antibody immunoassay were cut using 
a CO2 laser cutter (Universal Laser Systems).  Devices were constructed from 10 mil 
Dura-lar (Blick Art Supplies) and 5 mil adhesive-backed Dura-lar (Blick Art 
Supplies).  The lateral flow channel was cut from 2 mil backed high-flow 
nitrocellulose (HF090, Millipore).  The reagent storage and release pads were cut 
glass fiber pads (Grade 8951, Alhstrom).  The wicking pad was cut from cellulose 
(C083, Millipore).  The plasma separation membrane was cut from a commercially 
available glass fiber filter (LF1, GE Healthcare Life Sciences).  
The paper-based HPV antibody immunoassays were assembled as shown in 
Figure 7-1.   The nitrocellulose strip has three consecutive test zones to capture 
anti-HPV 16 antibodies and one positive control capture location.  The test zones 
were created by pipetting 0.4 µL of HPV16 L1 VLPs on each test location.  After 
drying the devices at 37°C for ten minutes, 0.4 µL of HPV16 L1 VLPs were again 
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pipetted on each test location.  The first capture location was spotted with HPV16 
L1 VLPs diluted one to four (25 µg/mL) in phosphate buffered saline (PBS) and the 
second and third locations were spotted with HPV16 L1 VLPs diluted one to two in 
PBS (50 µg/mL).  The positive control location was spotted once with 0.4 µL of 44 
µg/mL human IgG (Thermo Fisher Scientific) diluted in PBS.   
The nitrocellulose strips were dried for one hour at 37°C. The nitrocellulose 
strips were then blocked by completely submerging in PBS with .05% v/v  Tween 
20 (Biolegend) , 5% w/v sucrose (Sigma Aldrich) and 0.25% w/v  
Polyvinylpyrrolidone (40 kD, Sigma Aldrich).  After blocking for 30 minutes, the 
strips were dried for 30 minutes at 37°C.  The devices were then completely 
assembled by placing the glass fiber pads, nitrocellulose strips, plasma separation 
membrane and wicking pad as depicted in Figure 7-1.  To create stable detection 
antibody, 40 nm diameter gold conjugated goat anti-Human IgG (50 OD, BioAssay 
Works) was diluted one-to-five in PBS with 1% w/v bovine serum albumin (BSA), 
5% sucrose (Sigma Aldrich) and 5% trehalose (Sigma Aldrich).  Five microliters of 
the diluted antibody gold conjugate was spotted on the detection antibody glass 
fiber pad.  The entire device was then dried overnight at room temperature. All 
devices were fabricated one day prior to clinical testing and stored at room 
temperature until use.  
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7.2.3. Clinical Testing 
The pilot study was performed with the approval of the Institutional Review 
Board of Baylor College of Medicine.   Informed consent was obtained from each 
subject.  Subjects were eligible for inclusion if they were 18 or older and had a 
history of being sexually active.  Subjects were ineligible if they had a history of 
diagnosis of any immunodeficiency disorder, diagnosis of HIV, Hepatitis B or 
Hepatitis C or if they were currently using steroids or other immune-suppressive 
medications.  After consent, subjects were asked a brief series of questions including 
the number of HPV vaccines he/she has received, the type of HPV vaccine and the 
number of sexual partners he/she had in the last six months.   
The complete supplies required for each test are shown in Figure 7-1.  A 
finger prick was performed using a high-flow microtainer lancet (BD Diagnostics).  
Blood was collected using a 20 µL microsafe capillary tube (Safe-Tec) and 
immediately dispensed onto the plasma separation membrane. While the plasma 
separated, PBS with .05% Tween 20 (PBST) was dispensed onto the glass fiber 
reagent pads.  A 20 µL exact volume transfer pipette was used to place 20 µL of 
PBST on both the first wash glass fiber pad and the detection antibody pad. A 40 µL 
exact volume transfer pipette was used to dispense PBST on the second wash pad.  
Next, the adhesive was exposed by peeling back the paper covering.  Once the 
plasma reached the minimum plasma line, shown in Figure 7-1, the device was 
folded in half to initiate the test by placing the glass fiber pads in direct contact with 
the main lateral flow strip.  If the plasma did not reach the minimum plasma line, the 
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test was considered invalid.  Plasma reached the plasma line after one to two 
minutes.  Completed tests were scanned at 800 dots per inch (DPI) using a flatbed 
color scanner 35 minutes after folding the device. 
Images were analyzed both subjectively and objectively to determine if the 
test result was positive or negative.  The images were randomized and given to 
three independent reviewers blinded to the HPV vaccine status of the tested 
 
Figure 7-1 Two-dimensional paper network for detecting human antibodies 
against HPV 16.  (A) Device overview. The device consists of a nitrocellulose membrane 
with HPV16 virus-like particles immobilized at three test zones, a cellulose wicking pad, 
a plasma separation membrane, and three glass fiber pads, one of which contains dried 
detection antibody, all adhered to a thin acetate sheet.  (B) All supplies needed to 
perform the assay at the point-of care. The supplies consist of the paper immunoassay 
device, 15 mL of phosphate-buffered saline with 0.05% Tween-20, an alcohol prep pad, a 
Band-Aid, a high-flow lancet, a 20 µL microsafe capillary tube and a 20µL and 40 µL exact 
volume transfer pipette 
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individual.  The reviewers were told to determine whether each test was positive 
based on the presence of signal at two or more test zones.   Images were also 
analyzed quantitatively; analysis was performed only on the green channel, where 
contrast is greatest for the gold detection system.  After selecting the green channel, 
the image was inverted so that higher pixel intensities corresponded to higher 
signal.  A fixed-size region of interest (ROI) was manually placed at each test zone 
and at the positive control site.  Three background ROIs, equal in size to the test 
zone ROIs, were automatically placed halfway between successive capture locations.  
In each row of the ROI, the pixel value corresponding to the 95th percentile was 
calculated.   The signal in each ROI was defined as the average of the 95th percentile 
value calculated for each row. The 95th percentile was chosen instead of the 
maximum value to mitigate the effect of debris in the test ROI.  Signal from the three 
background ROIs were averaged together to define the background signal for each 
device.  The signal-to-background ratio (SBR) was defined for each test zone 
location and positive control location by dividing the signal at each corresponding 
ROI by the mean background signal.  We plotted the mean signal to background 
ratio for each capture zone location and compared results for unvaccinated subjects 
and those who reported receiving one, two or three doses of the HPV vaccine.  
Differences in mean signal-to-background ratios were evaluated using an unpaired 
two-tailed Student’s t-test;  p-values of less than 0.05 were considered statistically 
significant.  
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7.2.4. Dried Reagent Storage 
To determine the stability of the dried reagents, a simplified device with only 
a single test zone location, shown in Figure 7-3, was fabricated.  The test zone was 
created by pipetting 0.4 µL of 50 µg/mL HPV16 L1 VLPs in PBS on the nitrocellulose 
test location. The positive control was created by spotting 0.4 µL of 44 µg/mL anti-
human IgG at the control location.  The nitrocellulose was then dried for 10 minutes at ͵͹˚C. Another Ͳ.Ͷ µL of ͷͲ µg/mL (PVͳ͸ Lͳ VLPs was pipetted onto the test zone and the nitrocellulose was dried for an additional ͸Ͳ minutes at ͵͹˚C.  The 
nitrocellulose was blocked and dried reagent pads were prepared identically to the 
paper-based HPV antibody immunoassay used for clinical testing.  After the devices 
dried overnight, they were placed in a 4.5 mil thick Mylar foil pouch (Impak, Los 
Angeles) with two grams of molecular sieve (Impak, Los Angeles).  Three assembled 
stability testing devices were placed in each bag.  The foil pouches were sealed using 
a constant heat bag sealer.  Three of the devices were tested immediately and the 
remaining devices were then placed in a chamber at 37°C with 85% relative 
humidity.  The remaining devices were tested at 10, 15, 20 and 30 days after being 
exposed to high heat and humidity.    
Plasma from an individual who had received three Gardasil HPV vaccines 
was used as the sample for all devices.  Collection of blood was approved by the Rice 
University Institutional Review Board.  10 mL of blood was collected into a citrate 
dextrose solution A tube from a venous draw by a certified phlebotomist.   The 
blood was then centrifuged at 1,000 x g for 10 minutes at 4°C.  The supernatant 
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plasma was collected and centrifuged at 10,000 x g for 10 minutes at 4°C.  The 
plasma was then aliquoted and stored at -20°C until needed for testing.   
To test the devices at each time point, the glass fiber pads were rehydrated 
using the exact volume transfer pipettes as described above.  Then, 5 µL of the 
collected plasma was pipetted onto the sample glass fiber pad.  Once the plasma 
reached the minimum plasma line, the sample glass fiber pad was removed and the 
device was folded to initiate flow.   This is to prevent the presence of the glass fiber 
pad from affecting the flow profiled of the stability testing lateral flow strip. This 
step is not needed in the paper-based HPV antibody clinical test because flow from 
the plasma separation membrane ceases after red blood cells reach the 
nitrocellulose.  After 35 minutes, images were obtained at 800 DPI using a flatbed 
scanner.  Image analysis was performed similarly to the procedure using for the 
standard device. Fixed-size ROIs were manually placed at the test capture location 
and positive control location.  Background ROIs of the same size as the test ROIs 
were automatically selected midway between the test zone and positive control 
location and midway between the positive control location and wicking pad.  
Analysis was then performed identically to the standard device. 
7.3. Results and Discussion  
 Thirty-five subjects were enrolled in the study to evaluate the ability of the 
paper based HPV antibody immunoassay to determine HPV vaccination status.  
After the first five subjects, the device blocking method was modified to improve 
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device stability at ͵͹˚C.  The original blocking solution included ʹ% BSA which 
degraded in the presence of high heat.  The blocking procedure was modified as 
described in the methods.  Results from the first five subjects are thus not included 
in the analysis.  For the remaining 30 tests, the plasma failed to reach the minimum 
plasma line for two subjects.  A summary of the data from the remaining 28 patients 
is provided in Table 7-1.   After 35 minutes, the positive control signal was visible in 
all 28 devices, indicating completion of the assay.   
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 No HPV 
Vaccines 
One HPV 
Vaccine 
Two HPV 
Vaccines 
Three HPV 
Vaccines 
Number of 
Volunteers 
10 3 5 10 
Median age (years) 
(range) 
28 
(23-43) 
24 
(23-25) 
28.5 
(22 – 34) 25 (23 – 35) 
Average time since 
last vaccine (years) 
(range) 
- 
3.5 
(0.5-8) 
7.9 
 (0.75-16) 
4.8 
(0 – 12) 
Table 7-1: Summary of subjects in paper-based HPV VLP immunoassay pilot 
study 
Example images of completed paper-based HPV antibody immunoassays for 
individuals who reported receiving zero, one, two and three HPV vaccines are 
provided in Figure 7-2. All 15 tests from subjects who reported receiving two or 
three doses of the HPV vaccine, were judged positive by all three observers based on 
the presence of signal at least two test zones.  Twelve of the thirteen tests from 
subjects who reported receiving one or zero doses of the HPV vaccine were judged 
negative by all three observers.  One test from an unvaccinated subject was judged 
negative by one reviewer and positive by two reviewers.   
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Figure 7-2 Quantitative results of the pilot study.  Representative images of 
the paper-based HPV VLP immunoassay after 35 minutes for individuals who 
received (A) Three doses of HPV Vaccine, (B) Two doses of HPV vaccines, (C) One 
dose of HPV Vaccine and (D) No HPV vaccine.   (E) Average signal-to-background 
ratio at each test zone stratified by number of HPV vaccines received 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-2E shows a quantitative comparison of the signal-to-background at 
each capture location for subjects stratified by the number of HPV vaccines they 
reported receiving  The mean SBR is significantly higher for individuals who 
reported receiving three vaccines than for unvaccinated individuals and individuals 
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who reported receiving one vaccine (p<0.01) The mean SBR from subjects who 
received two vaccines was significantly higher than that for unvaccinated subjects 
and for subjects who reported receiving a single HPV vaccine (p<0.01).  There were 
no statistically significant differences in the SBR at any test zone between subjects 
who received two or three HPV vaccines. Similarly, there were no significant 
differences between the mean SBR of tests from unvaccinated subjects in 
comparison to subjects who had received a single HPV vaccine.    
The results of stability testing are shown in Figure 7-3.  After 10 days of 
storage, the SBR decreased by 7% at the test zone and by 17% at the positive 
control zone.  From day 10 to day signal decreased by 3.3% at the test zone and 
6.8% at the control zone.  Fluctuations in the SBR between these two time points are 
likely a result of device-to-device variability.  The Eppendorf Research Plus pipette 
used for spotting the capture antibodies on the nitrocellulose strips has a random 
error of ± 6% at the volume being dispensed.  To reduce the variability between 
devices, automated liquid dispensers are needed.  However, despite this variably the 
test could still discriminate unvaccinated individuals and individuals who reported 
having a single vaccine from those who reported receiving two or more HPV 
vaccines.    
The initial results of this test are promising; however, a large-scale study is 
necessary to understand the repeatability and robustness of the paper-based HPV 
VLP immunoassay.   A false positive was recorded by two reviewers.  It is possible 
the faint signal seen in this device was due to a previous natural HPV16 infection.  
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We chose to include only subjects with a history of sexual activity to increase the 
likelihood of participants having a history of natural HPV infection; however, we do 
not know the natural history of infection for any participants.  To reduce the 
likelihood of false positives, future iterations of the immunoassay could use HPV16 
L1 VLPs at one test zone and HPV18 L1 VLPs at a second test zone.  In future testing, 
device imaging or visual interpretation should occur as soon as the positive control 
signal is visible instead of a fixed duration of 35 minutes.  This will allow for a faster 
time to result in most cases.  The appropriateness of this assay design also depends 
on ongoing research evaluating long-term efficacy of two versus three dose HPV 
vaccination regimens.  
A primary limitation of this study was reliance of self-reporting of HPV 
vaccine status.  There are several factors which lead us to believe that the accuracy 
of this self-reporting is higher than that in the study reported by Stupiansky et al.2.  
The subjects in the Stupiansky et al. study were ages 14 to 17.  In this study, all 
participants were pursuing or had completed post-graduate education in biomedical 
sciences and actively volunteered to participate in an HPV-vaccine related study.  
Two subjects reported they were unsure if they had received two or three HPV 
vaccines.  They called their primary care physician and verified the number of HPV 
vaccines they had received before participating.  All other subjects reported being 
confident in their HPV vaccination history.  In future studies, medical records should 
be obtained to ensure accuracy of the participants HPV vaccination history.  
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Figure 7-3: Stability testing of paper-based HPV VLP immunoassays. Devices were stored at ͵͹˚C and 85% relative humidity for 30 days.   Each device 
contained a test zone and positive control zone.  The same sample, plasma from 
an individual who had received 3 HPV vaccine, was used for to evaluate the 
performance of the devices.  The mean signal-to-background ratio decreased 
10% over the course of 30 days at the test zone and 23% at the positive control 
zone. 
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 Chapter 8
Chapter 8: Conclusions 
8.1. Summary 
Cervical cancer is a major global health concern that disproportionately 
affects those living in low resource settings.  Novel screening and diagnostic 
techniques are needed to reduce the burden of disease globally.  In vivo imaging 
techniques and point-of-care molecular diagnostics can be used in tandem to help 
achieve this goal.  Simultaneously, HPV vaccination programs must be efficiently 
implemented globally to reduce the future impact of HPV-related cancer.  Rapid 
immunoassays can also help to achieve this goal. 
This dissertation begins by evaluating the diagnostic accuracy of the HRME 
to identify precancerous lesions of the cervix.  Several different morphological 
parameters were evaluated.  In a study evaluating HRME images from 59 patients 
referred for colposcopy based on an abnormal Pap test, HRME images from 
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colposcopically abnormal sites were classified as neoplastic or non-neoplastic with 
92% sensitivity and 77% specificity using median nuclear eccentricity and mean 
nuclear area.  A second study evaluating HRME images from an additional 228 
patients found similar sensitivity using four classification methods. However, while 
multiple methods showed high sensitivity, they were all limited in terms of 
specificity.  Classification using the number of abnormal nuclei per unit area and 
using nuclear-to-cytoplasmic ratio both showed 98% sensitivity in detecting lesions 
of grade CIN3 or higher.  Due to the critical nature of detecting these neoplastic 
cases, both of these modalities show promise for future studies.  Additional 
parameters may be necessary to increase specificity.  
In addition to evaluating the diagnostic performance of the standard HRME 
system, a smaller, less expensive cell-phone based mHRME was developed and 
characterized.  Rapid improvement in mobile phone technology provides a unique 
opportunity to create point-of-care optical diagnostic tools.  The mHRME achieves 
sub-cellular resolution and was successfully used to image normal and dysplastic 
cervical squamous epithelium in vivo.   
This dissertation also reports the design and testing two paper-based 
immunoassays.  Paper-based rapid diagnostic tests offer unique attributes making 
them amenable to low-cost point-of-care diagnostics.  The first immunoassay 
reported in this dissertation is a highly-sensitive two-dimensional paper network 
for the detection of the malarial antigen Pf HRP2.  This test achieves a limit of 
detection comparable to the best reported standard ELISA for this antigen.  With the 
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development of HPV E7 antibodies, this platform could be utilized to create a unique 
HPV oncoprotein screening test. A similar paper-based immunoassay was also developed for the evaluation of an individual’s (PVͳ͸ VLP immune response in 
order to ascertain HPV vaccination status.  Initial results suggest this test could help 
to distinguish between those who have received more than one HPV vaccine and 
those who have not.   
8.2. Future Work 
The work in this dissertation provides the groundwork for developing new 
low-cost cervical cancer screening and diagnostic tests.  In order to develop 
clinically impactful tools, several important steps remain.  First, the HRME must 
continue to be refined to optimize cost, user-friendliness and diagnostic 
performance.  Increasing specificity while maintaining sensitivity is paramount to 
the success of the device.  Alternative morphological parameters or additional 
contrast agents may be necessary in order to discriminate between high grade 
dysplasia and benign abnormalities of the cervix.  In future studies, a single image 
should be taken from each macroscopically abnormal location of the cervix instead 
of a short video.  Analysis should then be performed immediately and the HRME 
diagnosis recorded. These changes are critical to move towards a more fully-
automated approach. 
The mHRME offers a lower cost, smaller device, but has several limitations.  
First, the mHRME requires modifications to work for different mobile phones.  
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Second, it is not as robust as the standard HRME.  If the mHRME is to be used in 
clinical settings, a collaborative effort is needed consisting of clinicians, mechanical 
engineers and software engineers.  The clinicians are needed to guide the design 
process to create a practical, user-friendly device.  Mechanical engineers are needed 
to improve device stability and compatibility with multiple phones.  Finally, 
software engineers are needed to write a custom Android application capable of 
quantifying nuclear morphological features in near real time.   
The highly-sensitive 2DPN presented for malaria is a promising first step to 
create an HPV oncoprotein screening test.  However, a substantial amount of 
research is left to meet this goal.  First, high quality antibodies for the detection of 
high-risk HPV E7 proteins are needed.  Commercially available antibodies for this 
antigen are very limited.  Second, spiked FBS samples were used in the malarial 
antigen 2DPN proof-of-concept.  For the HPV oncoprotein immunoassay, samples 
would be obtained from cervical swabs.  Before running these samples on a 2DPN, 
samples would need to be lysed, purified and possibly concentrated.  Research is 
needed to develop sample preparation amenable to the point-of-care in order to 
produce an HPV oncoprotein immunoassay. 
Finally, the proof-of-principle paper-based HPV VLP immunoassay provides 
initial results suggesting utility in rapidly assessing an individual’s immune 
response to HPV16.  However, a large-scale study including verification with patient 
medical records and HPV DNA testing is necessary to fully understand the 
repeatability, robustness and limitations of this assay.  A new immunoassay using 
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one HPV16 test zone and one HPV18 test zone should be explored in order to help 
differentiate between individuals with a history of HPV infection and those who 
have received the vaccine.  
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